Repair of Acute Respiratory Distress Syndrome in COVID-19 by Stromal Cells (REALIST-COVID Trial): A Multicentre, Randomised, Controlled Trial

Ellen A Gorman (MB BCh BAO, 0000-0002-6020-1985)¹, Jennifer Rynne (0000-0002-8945-8434)², Hannah J Gardiner (MB BCh BAO)¹, Anthony J Rostron (PhD, 0000-0002-9336-1723)^{3,4}, Jonathan Bannard-Smith (MB ChB, 0000-0001-7120-480X)⁵, Andrew M Bentlev (MD, 0000-0002-6883-9246)⁶, David Brealey (MBBS, 0000-0002-1982-3379)⁷, Christina Campbell (BSc, 0000-0002-8446-523X)⁸, Gerard Curley (PhD, 0000-0003-0271-195X)⁹, Mike Clarke (DPhil, 0000-0002-2926-7257)⁸, Ahilanadan Dushianthan (PhD, 0000-0002-0165-3359)^{11,12}, Phillip Hopkins (PhD, 0000-0002-3713-8391)¹³, Colette Jackson⁸, Kallirroi Kefela (MD)¹⁴, Anna Krasnodembskaya (PhD, 0000-0002-2380-5069)¹, John G Laffey (MD, 0000-0002-1246-9573)¹⁵, Cliona McDowell (MSc)⁸, Margaret McFarland (MSc)¹⁶, Jamie McFerran (BSc)⁸, Peter McGuigan (MB BCh BAO)^{1, 16}, Gavin D Perkins (MD, 0000-0003-3027-7548)^{17,18}, Jonathan Silversides (PhD, 0000-0002-9562-5462)^{1,16}, Jon Smythe (PhD)¹⁹, Jacqui Thompson (BSc)²⁰, William S Tunnicliffe²¹, Ingeborg DM Welters (MD/PhD, 0000-0002-3408-8798)^{22,23}, Laura Amado-Rodríguez (PhD, 0000-0002-8793-0213) ^{24,25,26}, Guillermo Albaiceta (0000-0002-9276-3253)^{24,25,26,27}, Barry Williams²⁸, Manu Shankar-Hari (PhD, 0000-0002-5338-2538)², Daniel F McAuley (MD, 0000-0002-3283-1947)^{1,16}, Cecilia M O'Kane (PhD, 0000-0002-7138-5396)^{1*}

1 Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK

2 Centre for Inflammation Research, The University of Edinburgh, Edinburgh, EH16 4TJ3 Sunderland Royal Hospital, South Tyneside and Sunderland NHS Foundation Trust,Sunderland, UK

4 Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK

5 Department of Critical Care, Manchester Royal Infirmary, Manchester, UK

6 Acute Intensive Care Unit, Wythenshawe Hospital, Manchester, UK

7 University College Hospital London, London, UK

8 Northern Ireland Clinical Trials Unit, Belfast, UK

10 Royal College of Surgeons in Ireland, Dublin, Ireland

11 University Hospital Southampton, Southampton, UK

12 NIHR Southampton Biomedical Research Centre, University of Southampton,

Southampton, UK

13 King's Trauma Centre, King's College Hospital, London, UK

14 Department of Critical Care, Royal Infirmary of Edinburgh, Edinburgh, UK

15 Regenerative Medicine Institute (REMEDI) at CÚRAM Centre for Research in Medical

Devices, University of Galway, Ireland

16 Department of Critical Care, Belfast Health and Social Care Trust, Belfast, UK

17 Critical Care Unit, University Hospitals Birmingham, Birmingham, UK

18 Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick,

Coventry, UK

19 NHS Blood and Transplant, Oxford, UK

20 NHS Blood and Transplant, Birmingham, UK

21 Queen Elizabeth Hospital Birmingham, Birmingham, UK

22 Intensive Care Unit, Royal Liverpool University Hospital, Liverpool, UK

23 Institute of Life Course Medical Sciences, University of Liverpool, Liverpool Centre for

Cardiovascular Science, Liverpool, UK

24 Centro de Investigación Biomédica en Red (CIBER)-Enfermedades Respiratorias. Instituto de Salud Carlos III. Madrid, Spain.

25 Instituto de Investigación Sanitaria del Principado de Asturias. Oviedo, Spain.26 Unidad de Cuidados Intensivos Cardiológicos. Hospital Universitario Central de Asturias.Oviedo, Spain.

27 Departamento de Biología Funcional. Instituto Universitario de Oncología del Principado de Asturias. Universidad de Oviedo. Oviedo, Spain

28 Independent patient and public representative, UK

Corresponding author: Professor Cecilia O'Kane, Welcome Wolfson Institute for Experimental Medicine, Queen's University Belfast, 97 Lisburn Road, Belfast, BT9 7BL, UK <u>c.okane@qub.ac.uk</u>

Author contributions: DFM and CO'K conceived the study. All authors made a substantial contribution to the protocol development and/or conduct of the study. CC and CMcD are the trial statisticians and have verified the clinical trial data included in this report. JR and MSH conducted the transcriptomic analysis and its interpretation and have verified data related to this. LAR, GA conceived and contributed to the conduct and interpretation of the deconvolution analysis. DFM, EG and COK prepared the first draft of the manuscript and all authors have contributed to the writing of the report and have reviewed and approved the final version.

Role of funding source and collaborators: The trial was funded by the Wellcome Trust Health Innovation Challenge Fund [reference 106939/Z/15/Z] and the Northern Ireland Health and Social Care Research and Development Fund for needs led research. The funders had no role in the study design, data collection, data analysis, data interpretation, or writing of this report. Orbsen Therapeutics Ltd. has granted a non-exclusive, trial-specific licence to the

Page 4 of 83

Cellular and Molecular Therapies Division of the National Health Service Blood and Transplant Service to manufacture ORBCEL-C to Good Manufacturing Practice standards for the REALIST trial. Orbsen Therapeutics Ltd. has had no role in the study design, data collection, data analysis, data interpretation, or writing of this report.

Running title: MSCs in COVID-19 ARDS (REALIST trial)

Descriptor: 4.4 Clinical Trials in Critical Care Medicine

Word count: 4259

At a Glance Commentary

Current scientific knowledge on the subject: Mesenchymal stomal cells (MSCs) have been tested as a possible therapy for ARDS due to their anti-inflammatory, pro-resolution and antimicrobial effects. Phase 2 studies to date in ARDS related to COVID-19 have shown conflicting results. An insufficient MSC dose and inhibition of MSC activity by corticosteroids used in the treatment of COVID-19 related ARDS have been suggested as reasons for lack of efficacy, and the longer term effects of MSCs in this population have not been studied.

What this study adds to the field: This study tested the largest dose of MSCs in COVID related ARDS to date. We showed that, although well-tolerated, this higher dose of MSCs did not affect surrogate markers of pulmonary dysfunction and was associated with a longer duration of ventilation. The longer duration of ventilation in MSC-treated patients was not associated with an increased incidence of interstitial lung disease at 12 month follow up. Mortality was similar in MSC and placebo treated patients. While the cohort had high rates of corticosteroid prescription, MSCs still drove significant changes in peripheral blood transcriptome, but this did not translate to clinical efficacy.

This article is open access and distributed under the terms of the Creative Commons Attribution 4.0 International License (<u>https://creativecommons.org/licenses/by/4.0/</u>). For reprints please contact Diane Gern (<u>dgern@thoracic.org</u>).

This article has an online data supplement, which is accessible from this issue's table of content online at www.atsjournals.org.

Abstract

Rationale

Mesenchymal stromal cells (MSCs) may modulate inflammation, promoting repair in COVID-19-related Acute Respiratory Distress Syndrome (ARDS).

Objectives

We investigated safety and efficacy of ORBCEL-C (CD362-enriched, umbilical cord-derived MSCs) in COVID-related ARDS.

Methods

This multicentre, randomised, double-blind, allocation concealed, placebo-controlled trial (NCT03042143) randomised patients with moderate-to-severe COVID-related ARDS to receive ORBCEL-C (400million cells) or placebo (Plasma-Lyte148).

Measurements

The primary safety and efficacy outcomes were incidence of serious adverse events and oxygenation index at day 7 respectively. Secondary outcomes included respiratory compliance, driving pressure, PaO₂/FiO₂ ratio and SOFA score. Clinical outcomes relating to duration of ventilation, length of intensive care unit and hospital stays, and mortality were collected. Long-term follow up included diagnosis of interstitial lung disease at 1 year, and significant medical events and mortality at 2 years. Transcriptomic analysis was performed on whole blood at day 0, 4 and 7.

Main Results

60 participants were recruited (final analysis n=30 ORBCEL-C, n=29 placebo: 1 in placebo group withdrew consent). 6 serious adverse events occurred in the ORBCEL-C and 3 in the placebo group, RR 2.9(0.6-13.2)p=0.25. Day 7 mean[SD] oxygenation index did not differ (ORBCEL-C 98.3[57.2], placebo 96.6[67.3]). There were no differences in secondary surrogate outcomes, nor mortality at day 28, day 90, 1 or 2 years. There was no difference in prevalence of interstitial lung disease at 1year nor significant medical events up to 2 years. ORBCEL-C modulated the peripheral blood transcriptome.

Conclusion

ORBCEL-C MSCs were safe in moderate-to-severe COVID-related ARDS, but did not improve surrogates of pulmonary organ dysfunction.

Abstract word count: 250

Keywords

Acute Respiratory Distress Syndrome; COVID-19; Mesenchymal Stromal Cells; Clinical trial

Introduction

Acute respiratory distress syndrome (ARDS) is characterised by acute hypoxaemic respiratory failure with bilateral radiographic opacities, not fully explained by cardiac failure or fluid overload, due to inflammatory mediated destruction of the epithelial-endothelial barrier (<u>1</u>, <u>2</u>). Incidences of ARDS in hospitalised patients with COVID-19 between 17% to 68% have been reported (<u>3</u>). While supportive therapy has been the mainstay of treatment for ARDS due to COVID-19 (<u>4</u>), recent trials have demonstrated corticosteroids and Interleukin-6 receptor antagonists reduce mortality (<u>5-7</u>). However, mortality remains unacceptably high (<u>6</u>), with a continued need to identify therapeutic agents in COVID-19 ARDS (<u>8</u>).

Mesenchymal stromal cells (MSCs) are a potential novel therapeutic in ARDS due to their pleiotropic immunomodulatory and reparative properties (9, 10). Mechanisms of MSC actions include paracrine secretion of immunomodulatory factors (11, 12), and an ability to transfer functional mitochondria to damaged cells (including alveolar epithelial cells (13) and immune cells (14, 15)). Preclinical studies have demonstrated MSCs can repair lung injury, restore alveolar fluid clearance, and improve lung compliance and oxygenation (16-18). Prior to the COVID-19 pandemic, MSCs had been investigated in early phase clinical trials in ARDS, which suggested MSCs were safe in this patient population (19-24). Since this trial began, several trials have investigated MSC products in patients with COVID-19 ARDS, and have similarly supported their safety (25-27).

Variation in manufacturing techniques can alter MSC function (<u>28-30</u>), so that MSC products are not necessarily equivalent. ORBCEL-C consists of a population of CD362-enriched allogeneic umbilical cord-derived MSCs which have shown potent activity in *in vitro* and *in vivo* models of ARDS (<u>28</u>, <u>31-33</u>). In addition to high efficacy, this product offers the

3

advantage of being more homogeneous and better characterised than MSCs isolated by the traditional method of plastic adherence. As a source of MSCs, umbilical cord is cost-efficient, readily available (usually disposed of as a waste product) and not associated with risks to the donor.

Prior to the REALIST research programme, ORBCEL-C had not previously been investigated in humans, though clinical trials of similar MSC products are now underway in patients with diabetic kidney disease (ORBCEL-M, NEPHSTROM, NCT02585622) and liver disease (ORBCEL-C, MERLIN, NCT02997878). In the phase 1 REALIST dose-finding study, patients with ARDS (unrelated to COVID-19) received escalating doses of a single intravenous of ORBCEL-C MSCs (3 cohorts of 3 patients receiving 100, 200 or 400 x10⁶ MSCs). There was no dose limiting toxicity in any dose cohort (<u>34</u>). The REALIST phase 2 trial aims to investigate the safety and efficacy of a single intravenous infusion of 400 x 10⁶ ORBCEL-C MSCs in patients with moderate to severe ARDS. In this study we report the effect of ORBCEL-C on lung physiological measurements, clinical outcomes, whole blood transcriptome and long-term follow-up in a cohort of patients with ARDS due to COVID-19. Recruitment to an additional cohort of patients with ARDS unrelated to COVID-19 is ongoing and will be reported separately. Some of these results have been reported in abstract form at conference meetings (<u>35, 36</u>).

Methods

Study design and population

REALIST-COVID was a multicentre randomised, double-blind, allocation concealed, placebo-controlled trial of ORBCEL-C MSCs in patients with ARDS due to COVID-19, in twelve intensive care units across the United Kingdom (UK). Full details of the study design are published (<u>37</u>), and are available in the Online Data Supplement. The trial was sponsored by Belfast Heath and Social Care Trust and approved by North-East York research ethics

4

committee (18/NE/0006) and the Medicines and Health products Regulatory Agency (EudraCT Number: 2017-000584-33). Trial registration NCT03042143.

In brief, following informed consent eligible patients who were mechanically ventilated within 72 hours of onset of moderate to severe ARDS due to COVID-19, were randomised (1:1) to receive a single intravenous infusion of either ORBCEL-C (400×10^6 CD362 enriched umbilical cord derived MSCs in 200ml Plasma-Lyte 148, see Online Data Supplement for manufacturing details including cell viability assessment), or placebo (Plasma-Lyte 148, 200ml). All other aspects of care were according to standard critical care guidelines (<u>4</u>).

Trial outcomes included both primary safety and primary efficacy outcomes. The primary safety outcome was the incidence of serious adverse events. Adverse events were collected until day-90 and details of adverse event reporting are available in the Online Data Supplement. The primary efficacy outcome was oxygenation index at day 7 (calculated as: mean airway pressure [cmH₂O] x FiO₂ x 100)/PaO₂[kPa]). Oxygenation index (OI) is a physiological index of the severity of ARDS that measures both impaired oxygenation and the amount of mechanical support delivered. OI independently predicts outcome in ARDS (<u>38</u>) and is widely reported as a surrogate outcome in ARDS trials (<u>20</u>, <u>39-41</u>). Secondary surrogate outcomes included indices of pulmonary and non-pulmonary organ dysfunction. OI at days 4 and 14; respiratory compliance, driving pressure, and PaO₂/FiO₂ (PF) ratio on days 4, 7, and 14; and organ failure as measured by the Sequential Organ Failure Assessment (SOFA) score on days 4, 7, and 14. Clinical outcome measures included extubation, reintubation, ventilator-free-days (VFDs) to day-28, duration of ventilation, length of intensive care unit (ICU), and hospital stay, as well as 28- and 90-day mortality. Long-term follow-up was conducted for mortality, significant medical events, and for evidence of

pulmonary dysfunction and interstitial lung disease on clinically indicated thoracic CT scans and pulmonary function tests.

Whole blood total RNA-sequencing was carried out on samples collected at day 0, 4 and 7 (see Online Data Supplement for details). Other exploratory translational studies detailed in the trial protocol were not conducted in this cohort, due to the UK's regulatory requirement to process all research samples from COVID 19-infected patients in a containment level (CL) 3 laboratory environment during this phase of the pandemic.

Statistical Analysis

Based on our data from a previous study in ARDS, the mean [SD] OI at day 7 in patients with ARDS is 62 [51] cmH₂O/kPa (<u>42</u>). A sample size of 56 subjects (randomised 1:1) would have 80% power at a two-tailed significance level of 0.05 using a two-sample t-test to detect a clinically significant difference in oxygenation index at day 7, the primary efficacy outcome, of 39 cmH₂O/kPa in OI between groups (<u>38</u>). In previous UK multicentre studies in the critically ill, less than 3% withdrew consent or were lost to follow-up (<u>43</u>, <u>44</u>), therefore the sample size was inflated to 60 patients to allow for a drop-out rate of 5%.

The primary efficacy analysis was on an intention-to-treat basis and was conducted on the last available data carried forward (imputed values). Sensitivity analyses were conducted by imputing extreme values (minimum and maximum) and mean substitution. *A priori* defined subgroup analyses were undertaken for the primary efficacy outcome and selected secondary outcomes (VFDs at day 28 and 28-day mortality) based on severity of inflammation (C-Reactive Protein and ferritin (<u>45</u>)), and PF Ratio. Statistical analysis was conducting using STATA v15.1. The statistical analysis plan, which was finalised before recruitment to the study completed, is provided in the Online Data Supplement.

6

Results

Patients

From 2nd April 2020 to 4th December 2020, 193 patients were screened for eligibility, of whom 133 were excluded (Figure 1). Screening and recruitment data at each site are provided in Figure E1 in the Online Data Supplement. 60 patients were recruited with 30 allocated to each group (Figure 1). One patient in the placebo group subsequently withdrew consent and was excluded from the analysis. The primary outcome was therefore available for 59 patients (30 in ORBCEL-C group and 29 in placebo group).

Baseline patient characteristics and supportive care were similar between the groups (Table 1), and patients were typical of a critically ill population with COVID-19 (<u>6</u>), with predominant respiratory failure indicated by the low PF ratio and high OI, and comparatively low SOFA score. Corticosteroid use was similar in both groups (90% in ORBCEL-C, 89.7% in placebo group). Approximately half of patients in each group received anti-viral therapy. No patients in this trial received Interleukin-6 receptor antagonists or convalescent plasma. Concomitant medications and adjuvant therapies are detailed in Table E1a/b in the Online Data Supplement. There were no differences between groups in the time of study drug administration measured from intensive care unit admission, mechanical ventilation initiation, or thaw of the study drug (Table E2, Online Data Supplement).

Primary safety outcomes

There were 6 serious adverse events in the ORBCEL-C group and 3 in the placebo group; risk ratio 2.9; 95% confidence interval 0.6 to 13.2; p=0.25 (Table 2). Study drug administration was well-tolerated with no significant difference between the groups in postinfusion (up to 5 hours) haemodynamics, arterial blood gases, PEEP, plateau pressure or temperature (Figure E2). The incidence of adverse events was similar in both groups. No serious adverse events were reported related to the study drug. One patient in the ORBCEL-C group had pyrexia within 24 hours of the study drug administration, reported as a prespecified infusion-related adverse event, and classified as an adverse reaction. One patient in the placebo group had pyrexia reported as an adverse reaction. No other adverse events were considered to be related to the study drug. A summary of adverse event classifications (Table E3a) and detailed listing of all adverse events reported (Table E3b) are provided in the online supplement. Thromboembolic events reported as adverse events are detailed separately (Tables E4a and E4b). During 1-year follow up, one additional instance of pulmonary emboli was identified on thoracic CT in the placebo group.

Primary efficacy outcomes

The primary unadjusted analysis for the primary efficacy outcome, using imputed data from the last available data carried forward, found no difference in OI at day 7 between the ORBCEL-C group (mean 98.3 [SD 57.2]) and placebo group (mean 96.6 [SD 67.3]; mean difference 1.8; 95% confidence interval 30.7 to 34.4; p=0.91) (Table 3). Adjusted analysis (for baseline age, PF Ratio, APACHE II, vasopressor use and site) did not alter this finding (Table E5a/b in Online Data Supplement). Observed values for OI at day 7 were available for n=18/30 in ORBCEL-C group and n=13/29 in placebo group. Reasons for missing OI at day 7 are listed in Table E5c in the Online Data Supplement and most commonly this was due to moving to pressure support ventilation. Sensitivity analysis (using multiple imputations, and analysis using observed values), per protocol analysis and analysis in the population with

Page 14 of 83

PCR-confirmed COVID-19 did not alter the findings (Tables E5d and E5e in the Online Data Supplement).

There were no important differences between ORBCEL-C and placebo treated groups in secondary surrogate outcomes of pulmonary and non-pulmonary organ function (Figure 2, Figure E3, Table E6). Clinical outcomes are reported (Table 4), although the study was underpowered for these. While there was no difference in the rate of successful extubation, there was an increase in the duration of ventilation in the ORBCEL-C group (19 days [IQR 13 to 30]) compared to the placebo group (12 days [IQR 7 to 20]; hazard ratio 0.5; 95% confidence interval 0.3 to 0.9; p=0.017) (Table 4, Figure 3). Mortality at day 28 or 90 was similar between groups [28-day mortality ORBCEL-C n=5 (16.7%), placebo n=6 (20.7%), risk ratio 0.8, 95% confidence intervals 0.3 to 2.4, p=0.69; 90-day mortality ORBCEL-C n=7 (23.3%), placebo n=8 (27.6%), risk ratio 0.8, 95% confidence intervals 0.4 to 2.0, p=0.71]. ORBCEL-C had no effect on oxygenation index at day 7 according to *a priori* defined subgroups for baseline oxygenation (PF ratio) and inflammation (C-Reactive protein and ferritin) (Table E7). ORBCEL-C treatment was associated with a statistically significant higher number of VFDs in the group with PF ratio >20kPa at baseline but not those with more impaired oxygenation (Table E8).

Long-term follow up is summarised in Table 5. One patient in the ORBCEL-C group died between day 90 and 1 year. Two patients in ORBCEL-C group were lost to follow up at 1 year. 41 survivors were remotely followed up for significant medical events at 1 year (n=20 in ORBCEL-C, n=21 in placebo group). No further patients had died at the 2-year timepoint. 31 survivors were remotely followed up for significant medical events at 2 years (n=17 in ORBCEL-C, n=14 in placebo group). One patient in placebo group withdrew consent for follow up at 2 years. Reported significant medical events were similar in both groups (Table 5 and Table E9 for description of significant medical events). Clinically indicated thoracic CTs were available for 13 patients (ORBCEL-C n=5/20, placebo n=8/21). CT evidence of interstitial lung disease was similar between groups. Pulmonary function test reports were available for 11/20 ORBCEL-C patients and 9/21 in the placebo group. Diffusing capacity for carbon monoxide was reduced in both groups, with median percentage predicted value of 62% (57 to 71.5) in the placebo group compared to 76% (IQR 74 to 91.5) in the ORBCEL-C group.

Laboratory analysis

C-Reactive Protein, total peripheral white blood cell counts, and neutrophil counts were similar in both groups (Figure E4). There were no trends to differences in renal or liver function test abnormalities in response to ORBCEL-C (Table E10). Routine clinical measurements of coagulation (prothrombin time, activated partial thromboplastin time, and fibrinogen) were similar between groups (Figure E5).

Transcriptomic analyses

Analyses framework is shown in the Online Data Supplement. At baseline, there were no differentially expressed genes (DEGS) between ORBCEL-C and placebo groups (Figure 4A). Within the ORBICEL-C group, and within the placebo group, over time (day 7 vs day 0) there were significantly more DEGS in the ORBCEL-C group (896 vs 169 Figure 4B, 4C), with only 48 concordant genes between the groups (Figure 4D, Figure E6). The Ingenuity Pathway Analysis (IPA) of DEGS over time (Figure 4E) highlight that the ORBCEL-C group affected pathways involved in senescence mechanisms (such as upregulated unfolded protein responses, and P53 signalling, and down regulated Sirtuin signalling). In contrast, the IPA of

DEGS over time in the placebo group highlight mainly immune responses to viral infection pathways (such as up regulated B cell signalling, upregulation of the interferon regulatory factor (IRF) family of transcription factors).

We then used established methods to deconvolute the whole blood transcriptome to determine the impact of allocation on proportions of leucocyte subsets (<u>46</u>). In the ORBCEL-C group, proportions of total B cells and natural killer cell subsets reduced overtime (Figure E7 in the Online Data Supplement). In contrast, in the placebo group, proportions of total T cells, monocytes, and plasmacytoid dendritic cell subsets increased over time (Figure E7 in the Online Data Supplement), consistent with the IPA analyses described above.

Discussion

The key finding of this study is that a single dose of 400x10⁶ ORBCEL-C was safe and well tolerated in the population of patients with COVID-ARDS. However, there were no differences in the primary efficacy outcome of oxygenation index at day 7, or in other secondary surrogate outcomes of systemic and pulmonary organ function at day 4, 7 and 14. While the study was underpowered for clinical outcomes, a prolonged duration of ventilation was reported in survivors in the ORBCEL-C group, but long-term follow-up of survivors showed no increased incidence of pulmonary disorders or other significant medical events. Whole blood transcriptome analyses provided evidence for biological activity of ORBCEL-C MSCs.

This phase 2 trial aimed to assess the safety of ORBCEL-C in a population of patients with COVID-19 ARDS. ORBCEL-C therapy was safe and well tolerated, with no significant differences between groups in the primary safety outcome, or in the incidence adverse events. In this study adverse events which were expected (and related to the underlying condition) were not reported unless considered by the site investigator to be associated with the study drug administration, or unexpectedly severe or frequent. This approach to reporting of adverse events (47) may not capture the true incidence of specific events. For instance, we report the number of thromboembolic events reported as safety events, however as thromboembolism is recognised to be associated with COVID-19 disease (48, 49) these events may have been considered related to the underlying disease and not reported as an adverse event.

No significant safety concerns in relation to MSC infusion in COVID respiratory failure were identified in this study nor in other clinical trials to date (25-27). The detailed long-term follow up showing similar 2 year mortality rates in both groups, and similar overall incidence of significant medical events (defined as events occurring after the 90-day adverse event reporting window which would otherwise fulfil the criteria for serious adverse events) supports the safety of ORBCEL-C. We note (non-statistically significant) 3 diagnoses of malignancy in the 2 year follow up period in the MSC treated group. While long-term follow up in critically ill patients is challenging (50), and indeed achieving follow-up in > 90 % of patients at 1 year and > 75% at 2 years is a strength of this study, we advocate this in other MSC trials to understand any potential long term adverse outcomes. Two other studies have reported safety outcomes of MSCs in COVID-19 patients at 1 year including vital status with some limited data on parenchymal lung disease (27, 51). Prior to the COVID-19 pandemic, a meta-analysis evaluating MSC administration in a range of clinical conditions (including 55

randomised controlled trials and 2696 patients) reported MSCs were associated with a risk of fever, but found no association with non-fever infusional toxicity, malignancy, infection, thromboembolism or death (52). The safety outcomes and long-term follow up in this trial adds to the body of evidence supporting the safety of MSCs in patients with COVID ARDS.

While the finding of an increased duration of ventilation in the ORBCEL-C treated group raises the question of harm, this should be interpreted with caution. First, the trial was not designed to have statistical power to evaluate clinical outcomes and with a small sample size firm conclusions should not be made (53). Second, the signal of increased duration of ventilation in the ORBCEL-C group was only seen in survivors and may have reflected both a more severe disease state and an increased risk of barotrauma (54). The similar frequency in both groups of interstitial lung disease on clinically indicated thoracic CTs within 12 months of follow up is reassuring, as is the lack of reduced gas transfer factor in the ORBCEL-C group (diffusing capacity in the placebo group is in fact lower). We acknowledge though that follow up was limited by lack of protocolised screening for evidence of interstitial lung disease.

There have now been several RCTs investigating MSCs in COVID-19. Kirkham *et al* report a meta-analysis of eight RCTs (including 165 patients treated with MSCs, and 151 control patients) investigating administration of MSCs to patients with severe or critical COVID-19 (55). MSCs were reported to reduce the relative risk of death (risk ratio 0.63 [95% CI 0.42 to 0.94]) but showed no difference in the absolute risk of death. Of note, the relative risk of death analysis was heavily weighted by one study which had a control group mortality of 80%, thus the population was not comparable to this study (56). More recently, Bowdish *and colleagues* reported a commercially funded trial investigating two infusions (2 x 10⁶)

13

cells/kg/dose) of Remestemecel-L (a bone marrow derived MSC product) in n=222 patients with moderate to severe COVID-19 ARDS and found no difference in the primary outcome of mortality at 30 days (<u>27</u>). Similarly, Monsel *and colleagues* investigated MSC administration in forty-five patients with mild to severe ARDS (three infusions of 1 x 10⁶ MSCs/kg/dose over 5 days) and found no difference in the primary outcome of change in the PF ratio between day 0 and day 7 (<u>26</u>). These later two trials recruited a population of patients with COVID-19 ARDS comparable to those recruited to the REALIST trial, though Monsel *et al* also recruited patients with mild ARDS. Of the trials reported in COVID-19, REALIST administered the greatest dose of MSCs (at an approximate dose of 6 x 10⁶ cells/kg). However, it is difficult to compare the dosing schedule of MSC products between trials as it is well recognised that variation in MSC source and manufacturing may lead to variation in their function (<u>28, 29</u>), so that MSC products are not equipotent.

Like in the REALIST study, corticosteroid use in both Monsel and Bowdish trials was high (approximately 80%) (<u>26</u>, <u>27</u>). Evidence regarding steroid and MSC interactions is conflicting. In pre-clinical experimental models steroids have been reported to reduce MSCs' immunomodulatory and anti-inflammatory effects and inhibit cell cycle, promoting apoptosis (<u>57</u>). However, in patients they retained immunomodulatory activity in Graft versus host disease in the presence of steroids (<u>58</u>). Our transcriptomic data support the concept that MSCs remained biologically active in the presence of corticosteroids, suggesting that the steroids did not cause significant cytotoxicity but our data do not exclude the possibility that steroids inhibited the pathways by which MSCs might improve outcome from ARDS.

Despite the lack of signal towards clinical efficacy even with a higher MSC dose in the REALIST trial, our study provides evidence for potential biological activity of ORBCEL-C

in the setting of COVID-19 ARDS treated with dexamethasone. Specifically, we observed differences in enriched immunological mechanisms over time, between the ORBCEL-C group and the placebo group, despite similar transcriptional profiles at baseline. Several of the pathways identified have been associated with pathobiology of ARDS such as senescence (59), unfolding protein response ($\underline{60}$) and DDOST biosynthesis (which is implicated in Advanced Glycosylation End Product pathways ($\underline{61}$, $\underline{62}$)), and are testable hypothesis in future studies.

That the MSC product in the REALIST trial had biological activity, but did not translate to efficacy, raises questions regarding the optimisation of MSC administration to achieve a therapeutic effect. Higher doses (up to 10 x 10⁶ MSCs/kg) have been tolerated in similar populations of patients with non-COVID-related ARDS (19-21), but have been associated with procoagulant effects when administered to healthy volunteers in a human model of endotoxemia (63). Repeated administration of lower MSC doses have been well-tolerated in patients with COVID-19 ARDS, as outlined in the aforementioned studies (26, 27), and it is possible that repeated administration of higher MSC doses, such as used in the REALIST trial, may be needed to achieve therapeutic efficacy. The optimal time of administration remains unclear. While pre-clinical evidence suggests administration early in the time course of ARDS development is beneficial (33), a clinical study reported by Shi et al suggests benefit at a later stage in the disease course (64). One hundred patients with established lung damage due to COVID-19 were randomised to receive either 40 x 10⁶ MSCs or placebo during their convalescence (median 45 days from symptom onset) and there was a reduction in solid component lung lesions on CT at day 28, and improved six-minute walk distance (64). Subgroup analyses have suggested there may be differential effects of MSCs in different patient groups with trends towards mortality benefit in younger patients (less than 65 years)

and diabetic patients (27), and in the REALIST trial there was a trend towards increased ventilator free days in less hypoxic patients (PF ratio >20), however given the small sample size in these analyses further exploration of these findings is required. As MSCs are responsive to their microenvironment and may express different phenotypes following administration (30), factors such as timing of administration and disease severity could have important impact on their biological activity. Thus, the lack of efficacy in patients with COVID-19 ARDS does not preclude benefit in patients with ARDS due to other causes and further work is required to understand the optimal patient populations that will benefit from MSCs.

The lack of established potency assay for MSCs is an area of unmet need within the wider field of MSC therapy. The cells used in the REALIST study had to meet a range of specific criteria (including cell surface markers, sterility and viability) after manufacture to allow product release. There is no evidence to suggest these cells are dissimilar to previously manufactured batches which had been investigated in preclinical *in vitro* or *in vivo* studies (28, 31-33). Cell viability assessment in this study was assessed after freeze-thaw cycles at the central manufacturing site (NHSBT). Cell viability was not further assessed at the time of study drug preparation at the cell therapy facility as 1) no further manufacturing steps (such as a wash to remove DMSO) were conducted at the cell therapy facility 2) many sites did not have technical experience to carry out a cell viability assessment at the central manufacturing site. This is in contrast to the recently published study where cell therapy varied by site (20), where a further manufacturing step was undertaken to wash the MSCs and reduce the DMSO content, and this was found to adversely impact cell viability.

A limitation of this study included that data for the primary efficacy outcome, oxygenation index at day 7, were not available for all participants. In most cases this was unavoidable (related to extubation, death and mode of ventilation) and mitigations were in place, using imputed data, to minimise the impact of missing data. Furthermore, to minimise the risk of bias introduced by imputation, multiple methods of imputation were used and consistently demonstrated no difference in the primary outcome.

In conclusion, this phase 2 randomised controlled trial demonstrated that ORBCEL-C MSCs were safe, well tolerated in a population of patients with moderate to severe ARDS due to COVID-19. This early phase 2 study did not demonstrate improvements in surrogates of pulmonary organ dysfunction in a population of patients with COVID-19 related ARDS. The REALIST research programme is ongoing and currently investigating ORBCEL-C MSCs in a cohort of patients with ARDS unrelated to COVID-19.

Acknowledgements

The authors would like to acknowledge all patients and their legal representatives who participated in the REALIST trial; clinical research teams at each clinical site who participated in patient recruitment, data collection and patient follow up; clinical teams at each site who provided clinical care to patients involved in the study; pharmacy and cell therapy facility staff at each clinical site for oversight and management of the study drugs; staff at NHSBT involved in the manufacture and distribution of ORBCEL-C; staff at Victoria Pharmaceuticals involved in the manufacture and distribution of placebo; staff at Northern Ireland Clinical Trials Unit for support in conduct of the trial; staff at Queen's University, Belfast who supported laboratory analysis; members of the data monitoring and ethics committee (Professor John Norrie, Professor Mervyn Singer and Professor Sam Janes); members of the trial steering committee (Professor Charles Hinds, Professor John Simpson, Professor Mike Grocott, Mr Barry Williams and Professor John Laffey). We would like to acknowledge Dr David Oliver Hamilton for his effort in recruiting patients at Liverpool Royal Infirmary.

References

1. Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, *et al.* Acute respiratory distress syndrome: the Berlin Definition. *JAMA* 2012; 307: 2526-2533.

2. Gorman EA, O'Kane CM, McAuley DF. Acute respiratory distress syndrome in adults: diagnosis, outcomes, long-term sequelae, and management. *The Lancet* 2022; 400: 1157-1170.

3. Tzotzos SJ, Fischer B, Fischer H, Zeitlinger M. Incidence of ARDS and outcomes in hospitalized patients with COVID-19: a global literature survey. *Critical Care* 2020; 24: 516.

4. Griffiths MJD, McAuley DF, Perkins GD, Barrett N, Blackwood B, Boyle A, *et al.*Guidelines on the management of acute respiratory distress syndrome. *BMJ Open Resp Res* 2019; 6: e000420.

5. Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, *et al.* Dexamethasone in Hospitalized Patients with Covid-19. *N Engl J Med* 2021; 384: 693-704.

6. REMAP CAP Investigators. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. *New England Journal of Medicine* 2021; 384: 1491-1502.

7. Chaudhuri D, Sasaki K, Karkar A, Sharif S, Lewis K, Mammen MJ, *et al.* Corticosteroids in COVID-19 and non-COVID-19 ARDS: a systematic review and meta-analysis. *Intensive Care Medicine* 2021; 47: 521-537.

8. Horie S, McNicholas B, Rezoagli E, Pham T, Curley G, McAuley D, *et al.* Emerging pharmacological therapies for ARDS: COVID-19 and beyond. *Intensive Care Medicine* 2020; 46: 2265-2283.

9. Gorman E, Millar J, McAuley D, O'Kane C. Mesenchymal stromal cells for acute respiratory distress syndrome (ARDS), sepsis, and COVID-19 infection: optimizing the therapeutic potential. *Expert Review of Respiratory Medicine* 2021; 15: 301-324.

10. Horie S, Curley GF, Laffey JG. What's new in cell therapies in ARDS? *Intensive Care Medicine* 2016; 42: 779-782.

11. Fang X, Neyrinck AP, Matthay MA, Lee JW. Allogeneic human mesenchymal stem cells restore epithelial protein permeability in cultured human alveolar type II cells by secretion of angiopoietin-1. *J Biol Chem* 2010; 285: 26211-26222.

12. Nemeth K, Leelahavanichkul A, Yuen PS, Mayer B, Parmelee A, Doi K, *et al.* Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. *Nat Med* 2009; 15: 42-49.

13. Islam MN, Das SR, Emin MT, Wei M, Sun L, Westphalen K, *et al.* Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury. *Nat Med* 2012; 18: 759-765.

14. Jackson MV, Morrison TJ, Doherty DF, McAuley DF, Matthay MA, Kissenpfennig A, *et al.* Mitochondrial Transfer via Tunneling Nanotubes is an Important Mechanism by Which Mesenchymal Stem Cells Enhance Macrophage Phagocytosis in the In Vitro and In Vivo Models of ARDS. *Stem Cells* 2016; 34: 2210-2223.

15. Morrison TJ, Jackson MV, Cunningham EK, Kissenpfennig A, McAuley DF, O'Kane CM, *et al.* Mesenchymal Stromal Cells Modulate Macrophages in Clinically Relevant Lung Injury Models by Extracellular Vesicle Mitochondrial Transfer. *Am J Respir Crit Care Med* 2017; 196: 1275-1286.

16. McAuley DF, Curley GF, Hamid UI, Laffey JG, Abbott J, McKenna DH, *et al.* Clinical grade allogeneic human mesenchymal stem cells restore alveolar fluid clearance in human lungs rejected for transplantation. *Am J Physiol Lung Cell Mol Physiol* 2014; 306: L809-815.

17. Lee JW, Fang X, Gupta N, Serikov V, Matthay MA. Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung. *Proc Natl Acad Sci U S A* 2009; 106: 16357-16362.

18. Curley GF, Hayes M, Ansari B, Shaw G, Ryan A, Barry F, *et al.* Mesenchymal stem cells enhance recovery and repair following ventilator-induced lung injury in the rat. *Thorax* 2012;
67: 496-501.

19. Zheng G, Huang L, Tong H, Shu Q, Hu Y, Ge M, *et al.* Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study. *Respir Res* 2014; 15: 39.

20. Matthay MA, Calfee CS, Zhuo H, Thompson BT, Wilson JG, Levitt JE, *et al.* Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial. *Lancet Resp Med* 2019; 7: 154-162.

21. Yip HK, Fang WF, Li YC, Lee FY, Lee CH, Pei SN, *et al.* Human Umbilical Cord-Derived Mesenchymal Stem Cells for Acute Respiratory Distress Syndrome. *Crit Care Med* 2020; 48: e391-e399.

22. Lv H, Chen W, Xiang AP, Zhang Q, Yang Y, Yi H. Mesenchymal stromal cells as a salvage treatment for confirmed acute respiratory distress syndrome: preliminary data from a single-arm study. *Intensive Care Med* 2020; 46: 1944-1947.

23. Wilson JG, Liu KD, Zhuo H, Caballero L, McMillan M, Fang X, *et al.* Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. *Lancet Resp Med* 2015;
3: 24-32.

24. Bellingan G, Jacono F, Bannard-Smith J, Brealey D, Meyer N, Thickett D, *et al.* Safety and efficacy of multipotent adult progenitor cells in acute respiratory distress syndrome (MUST-ARDS): a multicentre, randomised, double-blind, placebo-controlled phase 1/2 trial. *Intensive Care Medicine* 2022; 48: 36-44.

25. Kirkham AM, Bailey AJM, Monaghan M, Shorr R, Lalu MM, Fergusson DA, *et al.* Updated Living Systematic Review and Meta-analysis of Controlled Trials of Mesenchymal Stromal Cells to Treat COVID-19: A Framework for Accelerated Synthesis of Trial Evidence for Rapid Approval—FASTER Approval. *Stem Cells Translational Medicine* 2022; 11: 675-687.

26. Monsel A, Hauw-Berlemont C, Mebarki M, Heming N, Mayaux J, Nguekap Tchoumba O, *et al.* Treatment of COVID-19-associated ARDS with mesenchymal stromal cells: a multicenter randomized double-blind trial. *Critical Care* 2022; 26: 48.

27. Bowdish ME, Barkauskas CE, Overbey JR, Gottlieb RL, Osman K, Duggal A, *et al.* A Randomized Trial of Mesenchymal Stromal Cells for Moderate to Severe ARDS From COVID-19. *American Journal of Respiratory and Critical Care Medicine* 2022.

28. De Witte SFH, Lambert EE, Merino A, Strini T, Douben HJCW, O'Flynn L, *et al.* Aging of bone marrow– and umbilical cord–derived mesenchymal stromal cells during expansion. *Cytotherapy* 2017; 19: 798-807.

29. De Witte SFH, Peters FS, Merino A, Korevaar SS, Meurs JBJV, O'Flynn L, *et al.* Epigenetic changes in umbilical cord mesenchymal stromal cells upon stimulation and culture expansion. *Cytotherapy* 2018; 20: 919-929.

30. Hoogduijn MJ, Witte SFHd, Luk F, Vroonhoven MCGNvdH-v, Ignatowicz L, Catar R, *et al.* Effects of Freeze–Thawing and Intravenous Infusion on Mesenchymal Stromal Cell Gene Expression. *Stem Cells and Development* 2016; 25: 586-597.

31. De Witte SFH, Merino AM, Franquesa M, Strini T, Zoggel JAAv, Korevaar SS, *et al.* Cytokine treatment optimises the immunotherapeutic effects of umbilical cord-derived MSC for treatment of inflammatory liver disease. *Stem Cell Research & Therapy* 2017; 8: 140.

32. Masterson C, Devaney J, Horie S, O'Flynn L, Deedigan L, Elliman S, *et al.* Syndecan-2positive, Bone Marrow-derived Human Mesenchymal Stromal Cells Attenuate Bacterialinduced Acute Lung Injury and Enhance Resolution of Ventilator-induced Lung Injury in Rats. *Anesthesiology* 2018; 129: 502-516.

33. Horie S, Masterson C, Brady J, Loftus P, Horan E, O'Flynn L, *et al.* Umbilical cordderived CD362(+) mesenchymal stromal cells for E. coli pneumonia: impact of dose regimen, passage, cryopreservation, and antibiotic therapy. *Stem Cell Res Ther* 2020; 11: 116.

34. Gorman E, Shankar-Hari M, Hopkins P, Tunnicliffe WS, Perkins GD, Silversides J, *et al.* Repair of acute respiratory distress syndrome by stromal cell administration (REALIST) trial: A phase 1 trial. *EClinicalMedicine* 2021; 41: 101167.

35. Gorman E, McAuley DF, Rostron AJ, Shankar-Hari M, Bannard-Smith J, Bentley AM, *et al.* Repair of Acute Respiratory Distress Syndrome in COVID-19 by Stromal Cell
Administration (REALIST-COVID) Phase 2 Randomised Controlled Trial. D94 PANDEMIC
OUTPUT: ALL THAT IS COVID-19: American Thoracic Society; 2022. p. A5285-A5285.

36. Gardiner HJ, Gorman EA, Rostron AJ, Shankar-Hari M, Bannard-Smith J, Bentley AM, *et al.* S44 Repair of acute respiratory distress syndrome in COVID-19 by stromal cells (REALIST-COVID trial): 1 year follow up for safety and pulmonary dysfunction. *Thorax* 2022; 77: A30.

37. Gorman E, Shankar-Hari M, Hopkins P, Tunnicliffe WS, Perkins GD, Silversides J, *et al.* Repair of acute respiratory distress syndrome by stromal cell administration (REALIST): a structured study protocol for an open-label dose-escalation phase 1 trial followed by a randomised, triple-blind, allocation concealed, placebo-controlled phase 2 trial. *Trials* 2022; 23: 401.

38. Seeley E, McAuley DF, Eisner M, Miletin M, Matthay MA, Kallet RH. Predictors of mortality in acute lung injury during the era of lung protective ventilation. *Thorax* 2008; 63: 994-998.

39. Toner P, Boyle AJ, McNamee JJ, Callaghan K, Nutt C, Johnston P, *et al.* Aspirin as a Treatment for Acute Respiratory Distress Syndrome: a randomised placebo controlled clinical trial. *Chest* 2021.

40. Wiedemann HP, Wheeler AP, Bernard GR, Thompson BT, Hayden D, deBoisblanc B, *et al.* Comparison of two fluid-management strategies in acute lung injury. *N Engl J Med* 2006; 354: 2564-2575.

41. McAuley DF, Cross LJM, Hamid U, Gardner E, Elborn JS, Cullen KM, *et al.* Keratinocyte growth factor for the treatment of the acute respiratory distress syndrome (KARE): a randomised, double-blind, placebo-controlled phase 2 trial. *Lancet Resp Med* 2017; 5: 484-491. 42. Craig TR, Duffy MJ, Shyamsundar M, McDowell C, O'Kane CM, Elborn JS, *et al.* A randomized clinical trial of hydroxymethylglutaryl- coenzyme a reductase inhibition for acute lung injury (The HARP Study). *Am J Resp Crit Care* 2011; 183: 620-626.

43. McAuley DF, Laffey JG, O'Kane CM, Perkins GD, Mullan B, Trinder TJ, *et al.* Simvastatin in the acute respiratory distress syndrome. *N Engl J Med* 2014; 371: 1695-1703.

44. Harvey S, Harrison DA, Singer M, Ashcroft J, Jones CM, Elbourne D, *et al.* Assessment of the clinical effectiveness of pulmonary artery catheters in management of patients in intensive care (PAC-Man): a randomised controlled trial. *Lancet* 2005; 366: 472-477.

45. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. *The Lancet* 2020; 395: 1033-1034.

46. Vallania F, Tam A, Lofgren S, Schaffert S, Azad TD, Bongen E, *et al.* Leveraging heterogeneity across multiple datasets increases cell-mixture deconvolution accuracy and reduces biological and technical biases. *Nature Communications 2018 9:1* 2018; 9: 1-8.

47. Cook D, Lauzier F, Rocha MG, Sayles MJ, Finfer S. Serious adverse events in academic critical care research. *Cmaj* 2008; 178: 1181-1184.

48. O'Donnell JS, Peyvandi F, Martin-Loeches I. Pulmonary immuno-thrombosis in COVID-19 ARDS pathogenesis. *Intensive Care Medicine* 2021; 47: 899-902.

49. Malas MB, Naazie IN, Elsayed N, Mathlouthi A, Marmor R, Clary B. Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis. *EClinicalMedicine* 2020; 29: 100639.

50. Wilcox ME, Ely EW. Challenges in conducting long-term outcomes studies in critical care. *Curr Opin Crit Care* 2019; 25: 473-488.

51. Shi L, Yuan X, Yao W, Wang S, Zhang C, Zhang B, *et al.* Human mesenchymal stem cells treatment for severe COVID-19: 1-year follow-up results of a randomized, double-blind, placebo-controlled trial. *EBioMedicine* 2022; 75: 103789.

52. Thompson M, Mei SHJ, Wolfe D, Champagne J, Fergusson D, Stewart DJ, *et al.* Cell therapy with intravascular administration of mesenchymal stromal cells continues to appear safe: An updated systematic review and meta-analysis. *EClinicalMedicine* 2020; 19: 100249.

53. Hackshaw A. Small studies: strengths and limitations. Eur Respir J 2008; 32: 1141-1143.

54. Nöbauer-Huhmann IM, Eibenberger K, Schaefer-Prokop C, Steltzer H, Schlick W,
Strasser K, *et al.* Changes in lung parenchyma after acute respiratory distress syndrome
(ARDS): assessment with high-resolution computed tomography. *Eur Radiol* 2001; 11: 2436-2443.

55. Kirkham AM, Bailey AJM, Shorr R, Lalu MM, Fergusson DA, Allan DS. Systematic review and meta-analysis of randomized controlled trials of mesenchymal stromal cells to treat coronavirus disease 2019: is it too late? *Cytotherapy* 2022.

56. Dilogo IH, Aditianingsih D, Sugiarto A, Burhan E, Damayanti T, Sitompul PA, *et al.* Umbilical cord mesenchymal stromal cells as critical COVID-19 adjuvant therapy: A randomized controlled trial. *STEM CELLS Translational Medicine*; n/a.

57. Li T, Xu Y, Wang Y, Jiang Y. Differential expression profiles of long noncoding RNAs and mRNAs in human bone marrow mesenchymal stem cells after exposure to a high dosage of dexamethasone. *Stem Cell Research & Therapy* 2021; 12: 9.

58. Kebriaei P, Isola L, Bahceci E, Holland K, Rowley S, McGuirk J, *et al.* Adult Human Mesenchymal Stem Cells Added to Corticosteroid Therapy for the Treatment of Acute Graft-versus-Host Disease. *Biology of Blood and Marrow Transplantation* 2009; 15: 804-811.

59. Evangelou K, Veroutis D, Paschalaki K, Foukas PG, Lagopati N, Dimitriou M, *et al.* Pulmonary infection by SARS-CoV-2 induces senescence accompanied by an inflammatory phenotype in severe COVID-19: possible implications for viral mutagenesis. *European Respiratory Journal* 2022: 2102951.

60. Bradley KL, Stokes CA, Marciniak SJ, Parker LC, Condliffe AM. Role of unfolded proteins in lung disease. *Thorax* 2021; 76: 92.

61. Vlassara H, Cai W, Goodman S, Pyzik R, Yong A, Chen X, *et al.* Protection against Loss of Innate Defenses in Adulthood by Low Advanced Glycation End Products (AGE) Intake: Role of the Antiinflammatory AGE Receptor-1. *The Journal of Clinical Endocrinology & Metabolism* 2009; 94: 4483-4491.

62. Griffiths MJD, McAuley DF. RAGE: a biomarker for acute lung injury. *Thorax* 2008; 63: 1034.

63. Perlee D, van Vught LA, Scicluna BP, Maag A, Lutter R, Kemper EM, *et al.* Intravenous Infusion of Human Adipose Mesenchymal Stem Cells Modifies the Host Response to Lipopolysaccharide in Humans: A Randomized, Single-Blind, Parallel Group, Placebo Controlled Trial. *Stem cells* 2018; 36: 1778-1788.

64. Shi L, Huang H, Lu X, Yan X, Jiang X, Xu R, *et al.* Effect of human umbilical cordderived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial. *Signal Transduct Target Ther* 2021; 6: 58.

27

Disclosures

EG received funding by the Wellcome Trust Health Innovation Challenge Fund [reference 106939/Z/15/Z] for the described work and received a travel scholarship to present this work at the American Thoracic Society. COK, DMcA, JL, JS & AK are investigators on the grant funding this work from Wellcome Trust Health Innovation Challenge Fund [reference 106939/Z/15/Z]. DMcA, COK & MC are investigators on a grant received from the Northern Ireland Health and Social Care Research and Development Division to fund this additional COVID-19 cohort during phase 2 of the REALIST trial. JL reports consulting fees from Baxter Healthcare and GlaxoSmithKline, provision of medicolegal reports to the Irish Clinical Indemnity Scheme, participation in DSMB for other clinical trials and is named on a patent for InspireShield, a device to reduce COVID-19 spread. AK reports grants received from MRC UK (MR/R025096/1 and MR/S009426/1) and a HORIZON 2020 MSC individual fellowship. MSH is supported by a NIHR Clinician Scientist Fellowship (CS-2016-16-011). GDP is supported by the Health Research (NIHR) Applied Research Collaboration (ARC) West Midlands and is a director of research for the Intensive Care Society. GC reports grants from Health Research Board (Ireland) Emerging Clinician Scientist Award and the United States Department of Defense Discovery Award. DMcA reports grants from NIHR, Innovate UK, MRC and Novavax as an investigator in ARDS and COVID-19 studies. DMcA reports consultancy fees unrelated to this work from Bayer, GlaxoSmithKline, Boehringer Ingelheim, Novartis and Eli Lilly. DMcA reports payments from GlaxoSmithKline as an educational seminar speaker. DMcA is a member of the DSMB for Vir Biotechnology, Inc and Faron Pharmaceuticals. DMcA has a patent for a novel treatment for inflammatory disease. DMcA is a director of research for the Intensive Care Society and Director of the EME programme for MRC/NIHR. DMcA reports a spouse who has received consultancy fees from INSMED and from the California Institute for Regenerative unrelated to this clinical trial. COK has

received consultancy fees from INSMED, unrelated to this work, and fees for participation in grant panels for the Californian Institute of Regenerative Medicine, unrelated to this clinical trial. COK reports a spouse who has received grants from NIHR, Innovate UK, MRC and Novavax. COK reports a spouse who has received consultancy fees unrelated to this work from Bayer, GlaxoSmithKline, Boehringer Ingelheim, Novartis and Eli Lilly. COK reports a spouse who has received payments from GlaxoSmithKline as an educational seminar speaker. COK reports a spouse who is a member of the DSMB for Vir Biotechnology, Inc and Faron Pharmaceuticals. COK reports a spouse who has a patent for a novel treatment for inflammatory disease. COK reports a spouse who is a director of research for the Intensive Care Society and Director of the EME programme for MRC/NIHR. All other authors report no declarations of interest. The views expressed in this publication are those of the authors and not necessarily those of the National Health Service, the National Institute for Health Research (NIHR), or the Department of Health and Social Care.

Data sharing statement

Data will be available to researchers on request subject to sponsor approval.

Figure legends

Figure 1: Consort Flow Chart

Figure 2: Oxygenation Index (OI, cm H_2O/kPa) over time from baseline (day 0) to day 14. Mean (SD) for observed values are presented. Reasons oxygenation index data not available at the specified timepoint are presented below the graph. *Mean Airway Pressure not recorded therefore not possible to obtain oxygenation index.

Figure 3: Kaplan Meier curve for duration of ventilation.

Data are presented separately for all patients (A), survivors (B), and non survivors (D).

Figure 4: Transcriptomic analysis of peripheral whole blood samples at day 0 (n=19 ORBCEL-C, n=23 placebo), day 4 (n=14 ORBCEL-C, n=14 placebo) and day 7 (n=18 ORBCEL-C and n=12 placebo).

A: Volcano plot comparing differentially expressed genes (DEGs) in the ORBCEL-C and placebo group at baseline (Day 0).

B: Venn diagram depicting the overlap of DEGs at day 7 compared to day 0 in the ORBCEL-C group (white) and the placebo group (grey).

C & D: Volcano plots comparing the time-dependent effects on DEGs (day 7 vs day 0) in the ORBCEL-C group (B) and the placebo group (C).

For A, C & D Padj <0.01, Log2 Fold Change (Log2FC) cut off -1<>1.

E: Heatmap of the top canonical pathways identified by Ingenuity Pathway Analysis (IPA) in both treatment groups.

	ORBCEL-C	Placebo	Total
	N=30	N=29	N=59
Gender, Male (%)	24 (80.0%)	20 (69.0%)	44 (74.6%)
Age, years	58.4 (9.2)	58.4 (12.5)	58.4 (10.8)
Weight, kg	93.1 (21.9)	92.8 (19.5)	93.0 (20.6)
Height, cm	168.8 (10.6)	168.4 (10.1)	168.6 (10.3)
Predicted body weight, kg	64.1 (10.7)	63.2 (10.8)	63.6 (10.7)
Temperature, °C	37.1 (1.2)	36.7 (1.0)	36.9 (1.1)
Assay	28 (93.3%)	26 (89.7%)	54 (91.5%)
COVID-19 Diagnosis			
Ethnicity			
Caucasian	23(76.7%)	20(69.0%)	43(72.9%)
Black	3(10.0%)	2(6.9%)	5(8.5%)
Asian	3(10.0%)	6(20.7%)	9(15.3%)
Unknown	0(0.0%)	0(0.0%)	0(0.0%)
Other	1(3.3%)	1(3.5%)	2(3.4%)
	1	<u> </u>	1
Baseline Severity			
APACHE II Score	13.2 (5.3)	13.7 (4.6)	13.5 (4.9)
Murray Lung Injury Score (LIS)	2.8 (0.4)	2.8 (0.5)	2.8 (0.4)

First Qualifying P/F Ratio	17.6 (4.1)	19.4 (4.9)	18.5 (4.6)
Worst PaO ₂ /FiO ₂ ratio	15.2 (4.2)	16.1 (5.4)	15.7 (4.8)
(Day 0/24 hrs prior to randomisation)			
Total SOFA Score	7.7 (3.4)	7.9 (3.1)	7.8 (3.2)
	n=29	n=27	n=56
Oxygenation Index	84.3 (26.0)	92.2 (44.6)	88.1 (36.0)
	n=29	n=27	n=56
Lowest Mean Arterial Pressure (mmHg)	69.7 (8.8)	70.6 (8.6)	70.1 (8.6)
Vasopressor Use	17 (56.7%)	15 (51.7%)	32 (54.2%)
Ferritin	1394.5 (617.4)	1728.8 (997.0)	1561.7 (830.2)
	n=13	n=13	n=26
CRP	145.3 (109.6)	136.6 (103.0)	141.1 (105.6)
		n=28	n=58
Ventilatory parameters			
PEEP (cmH ₂ O)	10.9 (2.6)	10.2 (2.7)	10.6 (2.7)
Plateau Pressure (cmH ₂ O)	24.0 (4.0)	23.6 (4.4)	23.8 (4.2)
	n=29	n=27	n=56
Driving Pressure (cmH ₂ O)	13.1 (4.4)	13.3 (5.0)	13.2 (4.6)
	n=29	n=27	n=56
Respiratory Compliance (ml/cmH ₂ O)	39.4 (22.3)	39.6 (21.0)	39.5 (21.5)
	n=29	n=27	n=56
Tidal Volume (ml/kg PBW)	7.1 (2.0)	7.5 (3.0)	7.3 (2.5)

SIMV	30 (100.0%)	27 (93.1%)	57 (96.6%)
PS	0 (0.0%)	2 (6.9%)	2 (3.4%)
Adjunctive Therapies			
Airway Pressure Release Ventilation	0 (0.0%)	1 (3.4%)	1 (1.7%)
High-Frequency Oscillatory Ventilation	1 (3.3%)	0 (0.0%)	1 (1.7%)
Neuromuscular Blocking Drugs	15 (50.0%)	12 (41.4%)	27 (45.8%)
Nitric Oxide	1 (3.3%)	2 (6.9%)	3 (5.1%)
Prone Position	8 (26.7%)	4 (13.8%)	12 (20.3%)

	ORBCEL-C	Placebo	Relative Risk	p-value
			(95% Confidence Intervals)	
Total Adverse Events	23*	16*	1.5 (0.8 to 2.7)	0.29
	15 (50%)†	10 (34.5%)†		
Adverse Reactions	1*	1*	0.97 (0.06 to 14.7)	1.00
	1 (3.3%)†	1 (3.4%)†		
Total Serious Adverse Events	6*	3*	2.9 (0.6 to 13.2)	0.25
	6 (20%)†	2 (6.9%)†		
Serious Adverse Reactions	0*	0*	-	-
(SAR)				
Suspected Unexpected Serious	0*	0*	-	-
Adverse Reactions (SUSAR)				
*Number of events				

Table 3: Oxygenation	ORBCEL-C n=30	Placebo n=29	Mean Difference (95% Confidence Interval)	p-value
Imputed				
Last value carried forward*	98.3 (57.2)	96.6 (67.3)	1.8 (-30.7 to 34.3)	0.91
Minimum value	91.0 (60.3)	87.7 (71.2)	3.3 (-31.0 to 37.7)	0.85
Maximum value	111.8 (55.3)	131.1 (87.4)	-19.3 (-57.3 to 18.7)	0.31
Mean substitution	100.0 (55.3)	103.5 (65.0)	-3.5 (-35.0 to 27.9)	0.82
Observed values	117.4 (64.5)	129.4 (87.8)	-12.0 (-67.8 to 43.9)	0.66
Mean (SD) presented	n=18 for intention-to-tr	n=13 eat population.		
*Primary Unadjusted	Analysis			

Table 4: Clinical or	utcomes				
		ORBCEL-C	Placebo	Mean Difference,	p-value
		n=30	n=29	Hazard ratio or	
				Relative Risk (95%	
				Confidence Interval)	
Time to 1st success	sful	22.0 (16.0-43.0)	17.0 (9.0-25.0)	0.6 (0.3 to 1.1)	0.079
extubation (days)*#	ŧ				
Incidence of extub	ation ^{‡,§}	24 (80.0%)	22 (75.9%)	1.1 (0.8 to 1.4)	0.70
Incidence of reintu	bation ^{‡,§}	2 (8.3%)	3 (13.6%)	0.6 (0.1 to 3.3)	0.56
Ventilation Free	Median	3.5 (0.0-11.0)	7.0 (0.0-18.0)	-	0.27
Days at day 28	[IQR] ^{II}				
	Mean (SD)	6.1 (7.3)	8.9 (8.9)	-2.7 (-6.9 to 1.5)	0.20
	††				
Duration of	All	19.0 (13.0-30.0)	12.0 (7.0-20.0)	0.5 (0.3 to 0.9)	0.017
Ventilation	Survivors	20.0 (16.0- 31.0)	10.0 (7.0-20.0)	0.4 (0.2 to 0.8)	0.007
(Days) ^{*,†}		n=25	n=22		
	Non-	13.0 (9.0-25.0)	12.0 (7.0-32.0)	1.4 (0.4 to 4.8)	0.62
	Survivors	n=5	n=7		
Length of ICU stay	/ (Days)*,†	24.0 (18.0-37.0)	18.0 (11.0-32.0)	0.6 (0.3 to 1.0)	0.064
Length of hospital	stay (Days) ^{*,†}	36.0 (26.0-53.0)	26.0 (17.0-39.0)	0.7 (0.4 to 1.2)	0.17
28 day mortality§		5 (16.7%)	6 (20.7%)	0.8 (0.3 to 2.4)	0.69
90 day mortality§		7 (23.3%)	8 (27.6%)	0.8 (0.4 to 2.0)	0.71

Mean (SD), median(IQR) or n(%) presented

*hazard ratio presented

[†]Censored at day 90

[‡]Number of patients with at least one occurrence.

[§]Relative Risk presented, p-value from chi-square (or fishers exact) presented.

^{II}Median [IQR] and p-value from Wilcoxon rank sum presented

^{††}Mean (SD) presented for treatment arms and mean difference (95% confidence interval), p-value from 2-

sample t-test.

Table 5: Long-term follow-up – mortality, signific	ant medical events	and clinically
indicated pulmonary function testing and Thorac	ic CT	
	ORBCEL-C	Placebo
Total no. patients in primary analysis	30	29
D28 Mortality (n,%)	5/30 (16.7)	6/29 (20.7)
D90 Mortality (n,%)	7/30 (23)	8/29 (27.5)
Loss to follow up#	2	0
1 year mortality (n,%)	8/28 (28.6)	8/29 (27.6)
2 year mortality (n,%)	8/28 (28.6)	8/29 (27.6)
Significant Medical Events		
Number followed up at 1 year	20	21
Number followed up at 2 years	20	20
No. of events	14	11
No. of patients (n,%)	11/20 (55)	9/21\$ (43)
Pulmonary Function Testing [*] - % predicted		
No. available (n,%)	11/20 (55)	9/21 (43)
Timing** (Days, median [IQR])	174 (119 to 291)	180 (123 to 230)
Forced expiratory volume in 1 sec (Median [IQR])	84 (74.5 to 92.5)	75 (73 to 86)
Forced vital capacity (Median [IQR])	75 (68.5 to 87.0)	73 (69 to 81)
Carbon monoxide diffusion capacity	n=10	n=8
(Median [IQR])	76 (74 to 91.5)	62 (57 to 71.5)
Pulmonary Function Testing [*] – Number less than	lower limit of norr	nal
Forced expiratory volume in 1 sec < 80% predicted	5/11 (46)	5/9 (56)
(n,%)		

Forced vital capacity <80% predicted	6/11 (55)	6/9 (67)
(n,%)		
Carbon monoxide diffusion capacity <80%	6/10 (60)	8/8 (100)
predicted (n,%)		
Thoracic CT*		
No. available (n,%)	5/20 (25)	8/21 (38)
Timing** (Days, median [IQR])	181 (157 to 198)	203 (95.5 to 233)
Evidence of interstitial lung disease (n,%)	4/5 (80)	6/8 (75)
Evidence of VTE (n,%)	0/5 (0)	1/8 (13)***
[#] For the two patients lost to follow up in the ORI	BCEL-C group the last a	vailable follow up

[#]For the two patients lost to follow up in the ORBCEL-C group the last available follow up information was at day-90.

*CT and pulmonary function testing data were collected from clinically indicated

investigations performed between day-28 and 1 year (+/- 30 days).

**Time from study drug administration to most recent PFTs or CT imaging.

***One additional VTE detected on clinically indicated Thoracic CT during follow up

between day 28 and 1 year (which was not reported by the site investigator as a safety event

as they considered it to be due to underlying disease – see Table 4a/4b).

&For n=1 in the placebo follow up for SMEs was only to year 1 as the patient withdrew

consent for SME follow up at year 2.

Figure 1




Figure 2






Figure 3



AJRCCM Articles in Press. Published May 08, 2023 as 10.1164/rccm.202302-0297OC Copyright © 2023 by the American Thoracic Society



Repair of Acute Respiratory Distress Syndrome in COVID-19 by Stromal Cells

(REALIST-COVID Trial): A Multicentre, Randomised, Controlled Trial

Ellen A Gorman, Jennifer Rynne, Hannah J Gardiner, Anthony J Rostron, Jonathan Bannard-Smith, Andrew M Bentley, David Brealey, Christina Campbell, Gerard Curley, Mike Clarke, Ahilanadan Dushianthan, Phillip Hopkins, Colette Jackson, Kallirroi Kefela, Anna Krasnodembskaya, John G Laffey, Cliona McDowell, Margaret McFarland, Jamie McFerran, Peter McGuigan, Gavin D Perkins, Jonathan Silversides, Jon Smythe, Jacqui Thompson, William S Tunnicliffe, Ingeborg DM Welters, Laura Amado-Rodríguez, Guillermo Albaiceta, Barry Williams, Manu Shankar-Hari, Daniel F McAuley, Cecilia M O'Kane.

ONLINE DATA SUPPLEMENT

Supplemental Methods

Hospital sites participating in the study

Guy's and St Thomas' Hospital, Guys' and Saint Thomas's NHS Foundation Trust Kings College Hospital, King's College Hospital NHS Foundation Trust University College Hospital, University College London Hospital NHS Foundation Trust Heartlands, University Hospital Birmingham NHS Foundation Trust Queen Elizabeth Hospital, University Hospital Birmingham NHS Foundation Trust Belfast City Hospital, Royal Victoria Hospital, and Mater Infirmorum, Belfast Health and Social Care Trust Liverpool Royal Infirmary, Liverpool and Broadgreen University Hospitals NHS Trust Manchester Royal Infirmary, Manchester University NHS Foundation Trust Southampton Hospital, University Hospital Southampton NHS Foundation Trust

Sunderland Royal Hospital, South Tyneside and Sunderland NHS Foundation Trust Wythenshawe Hospital, Manchester University NHS Foundation Trust

Edinburgh Royal Infirmary

Study participants

Eligible patients were mechanically ventilated within 72 hours of the onset of moderate to severe Acute Respiratory Distress Syndrome (ARDS, defined by the Berlin criteria (1)), with COVID-19 confirmed either by PCR or clinical diagnosis. Full inclusion and exclusion criteria are detailed below. Patients or their legal representatives provided informed consent.

Eligibility criteria
Inclusion criteria
1. Moderate to severe ARDS as defined by the Berlin definition
a. Onset within 1 week of identified insult.
b. Within the same 24-hour time period
i. Hypoxic respiratory failure (PaO ₂ /FiO ₂ ratio \leq 27 kPa on PEEP \geq 5 cm H ₂ 0)
ii. Bilateral infiltrates on chest X-ray consistent with pulmonary oedema not
explained by another pulmonary pathology.
iii. Respiratory failure not fully explained by cardiac failure or fluid overload.
2. The patient is receiving invasive mechanical ventilation.
3. COVID-19 based on clinical diagnosis or PCR test.
Exclusion criteria
1. More than 72 hours from the onset of ARDS.
2. Age <16 years.
3. Patient is known to be pregnant.
4. Major trauma in prior 5 days.
5. Presence of any active malignancy (other than non-melanoma skin cancer) that required treatment
within the last year.
6. WHO Class III or IV pulmonary hypertension.
7. Venous thromboembolism currently receiving anti-coagulation or within the past 3 months
8. Currently receiving extracorporeal life support (ECLS).
9. Severe chronic liver disease with Child-Pugh score >12.
10. DNAR (Do Not Attempt Resuscitation) order in place.
11. Treatment withdrawal imminent within 24 hours.
12. Consent declined.
13. Prisoners.
14. Non-English speaking patients or those who do not adequately understand verbal or written
information unless an interpreter is available.
15. Previously enrolled in the REALIST trial.

Randomisation and Masking

Participants were randomised (1:1) to receive either ORBCEL-C (400 x 10⁶ cells in 200mls) or placebo (Plasma-Lyte 148, 200mls), stratified by recruitment centre and vasopressor use. Patients were randomised by the research staff at the clinical site via an automated centralised 24-hour telephone or web-based randomisation system (CHaRT, Centre for Healthcare Randomised Trials, University of Aberdeen). The randomisation sequence was generated by the Northern Ireland Clinical Trials Unit statistician using NQuery Advisor using variable block sizes and saved in a restricted section of the trial management folder, which can only be accessed by the clinical trials unit statistician and not those who enrol or assign interventions. The investigator, treating physician, other members of the site research team and participants were unblinded to facilitate preparation of ORBCEL-C and distribution to cell therapy facilities serving the clinical sites. To maintain blinding, placebo was prepared in identical bags to the bags used to infuse the ORBCEL-C MSCs. The infusion bag was masked by an amber opaque bag in the cell therapy facility, and an opaque infusion set was used for MSC/placebo administration.

Study drug manufacture

The ORBCEL-C cellular product consisted of allogeneic donor anti-CD362 antibody enriched human UCderived mesenchymal stromal cells. It was manufactured to Good Manufacturing Practice standards as previously described (2). In brief (taken directly from reference 2), it was manufactured from three donors, and MSCs from different donors were not pooled during the manufacturing process. Cells isolated from umbilical cord tissue were first enriched for CD362 prior to culture in flasks to passage 2 or 3. Cells were subsequently expanded to passage 4 (P4) with Terumo Quantum® cell expansion system. Cells harvested at P4 were resuspended in Plasma-Lyte 148 buffer containing 2.5% Human Albumin Solution and an equal volume of CryoStor® CS10 cryoprotectant (DMSO 10%, BioLife Solutions, final DMSO concentration 5%) to achieve a concentration of cells of 10 x 10⁶ cells per ml. Cryopreserved drug product was stored at fixed cell doses of either 100 x10⁶, 200 x10⁶ or 400 x10⁶ cells in 10, 20 or 40 ml volumes respectively. The cryopreserved drug product was used within its validated shelf life (24 month validation at the onset of the trial, subsequently validated and extended to 36 months).

Final drug product release testing included appearance, morphology, sterility testing, endotoxin testing, post thaw cell count (trypan blue manual count), cell viability testing (minimum threshold >70% post thaw) and flow cytometry to confirm cell phenotype fulfils criteria of MSCs described by the international society for cellular therapy (ISCT) (minimum of 90% positive for MSC markers (CD90, CD73 and CD105) and cell purity exceeding 95% (based on maximum values of 5% expression of markers CD45, CD34 and HLA-DR)) (3). Cells also underwent mycoplasma analysis and karyotyping. Validation work has confirmed that a cell viability >70% is maintained for at least 6 hours following the thaw procedure.

Following manufacture, quality control testing and certification by a Qualified Person (QP), ORBCEL-C stock was distributed to cell therapy facilities (CTF) located in proximity to clinical sites for storage until required (taken from reference 2).

Placebo was Plasma-Lyte-148 200ml, an isotonic buffered crystalloid solution (4), Baxter Healthcare Ltd. The cell product was thawed at CTFs and diluted with Plasma-Lyte 148 to a total volume of 200mls for intravenous administration. Following dilution, the final DMSO concentration in the cellular infusion was 1%. To maintain blinding, care was taken to ensure the placebo was not released earlier than the typical time needed for preparation of the cell therapy product from the frozen cellular drug product. The study drug was transported to the clinical site at 2-8°C. Both the cellular product and the placebo had an equivalent 6-hour expiry date, which for the cellular product was the beginning of the thaw process.

Procedures

All patients received intravenous chlorphenamine 10mg before study drug administration, to reduce any histamine-mediated effects of dimethyl sulfoxide (DMSO) in the cell cryopreservant (5). The cells or matched placebo were administered over 30-90 minutes via a dedicated infusion line, through a standard blood component administration set with a 200 micron in-line filter, and within 6 hours of the start of the thaw process. Patients were monitored throughout the infusion and for five hours following completion of the infusion. All other aspects of care were according to standard critical care guidelines (6), including lung protective ventilation, and at the discretion of the treating physician. A schedule of assessments is provided below.

Schedule of assessments

	Day	Day	Day	Day 90	1 Year	2 Year						
	0	1	2-3	4	5-6	7	8-13	14	15-	(+/- 14	(+/- 30	(+/- 30
									28	days)	days)	days)
Eligibility												
assessment	X											
Informed consent	X											
Enrolment/	X											
Randomisation												
Baseline data	X											
Daily data		X	X	Х	Х	X	X	Х				
Chlorphenamine		X										
administration												
Study drug		X										
administration												
Adverse events		X	X	Х	Х	X	X	X	Х	Х		
Mortality									Х	Х	X	X
Medical Event											X	X

Adverse event reporting

Adverse events were reported to day-90. Events expected in this critically ill population were not reported as adverse events unless considered to be related to the study drug or unexpectedly severe or frequent.

The following pre-specified adverse events occurring within 6 hours of the start of infusion were collected

- 1. An increase in vasopressor dose greater than or equal to the following:
 - a. Norepinephrine: 0.1 mcg/kg/min
 - b. Epinephrine: 0.1 mcg/kg/min
 - c. Commencement of any vasopressor including norepinephrine, epinephrine, vasopressin, phenylephrine, and dopamine
- 2. New ventricular tachycardia, ventricular fibrillation or asystole
- 3. New cardiac arrhythmia requiring cardioversion
- 4. Hypoxemia requiring an increase in FiO₂ of 0.2 or more and an increase in PEEP of 5 or more to maintain SpO₂ in the target range
- 5. Clinical scenario consistent with transfusion incompatibility or transfusion related infection (e.g. urticaria, new bronchospasm).

The following pre-specified adverse events occurring within 24 hours of the start of infusion were collected:

- 1. Any death
- 2. Any cardiac arrest
- Temperatures recorded as >38.5°C or temperatures that are recorded as >38.5°C prior to study drug administration and have increased by ≥1°C.

Procedures for long-term follow up

Follow up for survival status and significant medical events

At hospital discharge patients' contact information and primary care details were recorded and stored centrally at the Northern Ireland Clinical Trials Unit (NICTU). A thank you note was sent to the patient to thank them for participation in the study and to remind them the trial team would contact them in the future for follow up. Mortality status was obtained from general practice and hospital records where possible and was collected by staff at NICTU at 1- and 2-year timepoints (+/- 30 days). Where possible the patient's status was established prior to direct contact with the patient.

Survivors were followed up for significant medical events at 1 and 2 years via patient telephone interview, medical record review, and/or contact with the primary care provider. Follow up was conducted centrally by two research physicians on behalf of NICTU, and supported by recruiting sites through review of hospital records. Where a patient was not contactable (after reasonable efforts to contact were made), medical records and/or contact with the primary care provider was used as the primary source of follow up information. Where a patient was not contactable, and no information was available on medical records or from a primary care provider, the patient was recorded as lost to follow up.

Significant medical events occurring up to the 1- and 2-year (+/- 30 days) timepoints are reported. A significant medical event was defined as any event which fulfilled criteria for a serious adverse event occurring beyond the adverse event reporting period (which was up to day 90). In addition, if evidence of interstitial lung disease was found, it was reported as a significant medical event if it was considered to be clinically significant (eg associated with new symptoms, treatment or the patient was under the care of (or referred to) a respiratory physician) and/or there was evidence of severe disease on computerised tomography (CT) imaging. A significant medical event was not recorded on the basis of abnormal pulmonary function tests alone. Significant medical events were reviewed by the Chief Investigator for causality and expectedness, and any event considered to be related to the study drug administration would have been reported as a serious adverse reaction and usual expediated adverse event reporting procedures would have been followed.

Extended follow up for evidence of pulmonary dysfunction and interstitial lung disease

Results of clinically indicated thoracic CT and pulmonary function tests (PFTs) occurring between day 28 and 1 year (+/-30 days) were collected and reviewed by a blinded assessor for evidence of pulmonary dysfunction and interstitial lung disease. Data collected included: thoracic CT reports, time from study drug administration to CT and pulmonary function testing (where more than one investigation had been performed, the time to the most recent investigation was used); percentage predicted forced vital capacity, forced expiratory volume in 1 second, and diffusion capacity for carbon monoxide where available.

Transcriptomic analysis

Sample collection and RNA isolation

Peripheral whole blood samples were collected into PAXgene Blood RNA tubes (PreAnalytiX) and stored at -20 to -80 °C. RNA was isolated according to the manufacturer's instructions using an automated QIAcube system (Qiagen). Total RNA quality and quantity was assessed using the Tapestation 4150 (Agilent) and the Qubit fluorometer (Life Technologies), respectively, according to the manufacturer's instructions.


RNA-sequencing

RNA strand-specific library preparation with globin depletion and poly(A) selection was performed using the NEBNext Globin and rRNA depletion kit, Poly(A) mRNA magnetic isolation module, and the Ultra II directional RNA library prep kit (New England Biolabs) with unique dual index primers, according to the NEB protocol. 100 ng of RNA were used as input for library preparation. RNA-sequencing was performed on a NovaSeq (Illumina) platform (150bp, paired end sequencing) to a depth of 25M paired-end reads per sample, carried out by Genewiz (Azenta Life Sciences).

Data analyses

Cancer cloud genomics (CGC) cloud resource was used for initial data analysis. *FastQC* was used to quality check the files and assess sequencing success (7). The raw sequencing FASTQ files were trimmed of sequencing adapters using *Trimmomatic* (8). Reads were aligned to the transcriptome and transcript abundances were estimated using *Salmon Quant* (8), using the human transcriptome file and gene annotation file from GENCODE (v38). Salmon quant files were imported to RStudio for all downstream analyses. Differential gene expression analysis was performed using *DeSeq2* (9). Treatment groups were compared at baseline and differential gene expression was performed on each group separately comparing changes over time. Treatment groups were compared at baseline and differential gene expression was performed on each group separately comparing changes over time. Genes with a Log2 fold change of >1 or <-1, and an adjusted p-value of <0.01, were considered to be differentially expressed and statistically significant (consistent with approaches used by others (10, 11). *ImmunoStates* was used for deconvolution of cell population proportions (12). Ingenuity pathway analysis (IPA) was performed to identify the top canonical pathways in each treatment group over time (13). For visualisation of the data using volcano plots, boxplots, principle component analysis (PCA) plots and heatmaps, the *Ggplot2* and *gplots* packages were used (14, 15). *Eulerr* was used to generate Venn diagrams (16).

Transcriptomic Analysis Framework



References for supplemental methods

1. Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, *et al.* Acute respiratory distress syndrome: the Berlin Definition. *JAMA* 2012; 307: 2526-2533.

2. Gorman E, Shankar-Hari M, Hopkins P, Tunnicliffe WS, Perkins GD, Silversides J, *et al.* Repair of acute respiratory distress syndrome by stromal cell administration (REALIST): a structured study protocol for an open-label dose-escalation phase 1 trial followed by a randomised, triple-blind, allocation concealed, placebo-controlled phase 2 trial. *Trials* 2022; 23: 401.

3. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, *et al.* Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy* 2006; 8: 315-317.

4. Weinberg L, Collins N, Van Mourik K, Tan C, Bellomo R. Plasma-Lyte 148: A clinical review. *World J Crit Care Med* 2016; 5: 235-250.

5. Kollerup Madsen B, Hilscher M, Zetner D, Rosenberg J. Adverse reactions of dimethyl sulfoxide in humans: a systematic review. *F1000Res* 2018; 7: 1746.

6. Griffiths MJD, McAuley DF, Perkins GD, Barrett N, Blackwood B, Boyle A, *et al.* Guidelines on the management of acute respiratory distress syndrome. *BMJ Open Resp Res* 2019; 6: e000420.

7. Anders S. Babraham Bioinformatics - FastQC A Quality Control tool for High Throughput Sequence Data. Soil; 2010.

8. Bolger AM, Lohse M, Usadel B. Trimmomatic: A flexible trimmer for Illumina sequence data. *Bioinformatics* 2014; 30: 2114-2120.

9. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biology* 2014; 15: 1-21.

10. Sarma A, Christenson SA, Zha BS, Pisco AO, Neyton LPA, Mick E, *et al.* Hyperinflammatory ARDS is characterized by interferon-stimulated gene expression, T-cell activation, and an altered metatranscriptome in tracheal aspirates. *medRxiv* 2022: 2022.2003.2031.22272425.

11. Ahern DJ, Ai Z, Ainsworth M, Allan C, Allcock A, Angus B, *et al.* A blood atlas of COVID-19 defines hallmarks of disease severity and specificity. *Cell* 2022; 185: 916-938.e958.

12. Vallania F, Tam A, Lofgren S, Schaffert S, Azad TD, Bongen E, *et al.* Leveraging heterogeneity across multiple datasets increases cell-mixture deconvolution accuracy and reduces biological and technical biases. *Nature Communications 2018 9:1* 2018; 9: 1-8.

13. Krämer A, Green J, Pollard J, Tugendreich S. Causal analysis approaches in ingenuity pathway analysis. *Bioinformatics* 2014; 30: 523-530.

14. Warnes G, Bolker B, Bonebakker L, Gentleman R, Galili T. gplots: various R programming tools for plotting data. 2022.

15. Wickham H. ggplot2. ggplot2 2009.

16. Larsson J, Godfrey J, Gustafsson P, Eberly D, Huber E, Slowikowski K, *et al.* eulerr: Area-Proportional Euler and Venn Diagrams with Ellipses. *Proceedings of International Workshop on Set Visualization and Reasoning* 2018; 2116: 84-91.

Supplemental Tables

- Table E1: Concomitant Medication during hospital stay
- Table E1b: Adjuvant therapies day 1 to day 14.
- Table E2: Timing of study drug administration
- Table E3a: Classification of Adverse Events
- Table E3b: Full listing of Adverse Events reported
- Table E4a: Venous Thromboembolism (VTE) and Pulmonary Emboli reported
- Table E4b: Detailed assessment of Venous Thromboembolism (VTE) and Pulmonary Emboli reported
- Table E5a: Adjusted analysis for Oxygenation Index (cmH₂O/kPa) at day 7
- Table E5b: Post-hoc adjusted analysis for Oxygenation Index (cmH2O/kPa) at day 7 (to include site)
- Table E5c: Reasons for missing observed data for Oxygenation Index at day 7
- Table E5d: Secondary analysis of oxygenation index (cmH2O/kPa) at day 7 in a per protocol population
- Table E5e: Additional analysis of oxygenation index (cmH₂O/kPa) at day 7 in patients with confirmed PCR COVID-19
- Table E6: Secondary outcomes pulmonary and non-pulmonary organ function
- Table E7: Subgroup analysis of oxygenation index (cmH2O/kPa) at day 7
- Table E8: Subgroup analyses for selected secondary outcomes
- Table E9: Extended follow up at 2 years mortality, significant medical events and clinically indicated
- pulmonary function testing and Thoracic CT
- Table E10: Clinical Laboratory Assessments at day 0, 4, 7, and 14

			ORBCEL-C	Placebo
		1	N=30	N=29
		Yes	15 (50.0%)	16 (55.2%)
	Anti-viral Medications	Keletra (Lopinavir/Ritonavir) 2 (6.7%)	3 (10.3%)
	Anti-vital Wedications	Remedesiv	r 11 (36.7%)	14 (48.3%)
	Othe	r 2 (6.7%%)	2 (6.9%)	
		Yes	4 (13.3%)	4 (13.8%)
		IL-6 blockad	e 0 (0.0%)	0 (0.0%)
		IL-1 blockad	e 0 (0.0%)	0 (0.0%)
		IF	V 0 (0.0%)	0 (0.0%)
Concomitant	Experimental Treatments	Macrolide	s 0 (0.0%)	0 (0.0%)
Medications (at any		Convalescent Plasm	a 0 (0.0%)	0 (0.0%)
point during hospital		Heparin/LMWH (not used for	r 3 (10.0%)	4 (13.8%)
stay)*		prevention/treatment of thrombosis)	l í í
		Othe	r 2 (6.7%)	0 (0.0%)
		Yes	27 (90.0%)	26 (89.7%)
		Hydrocortison	e 4 (13.3%)	7 (24.1%)
		Dexamethason	e 24 (80.0%)	23 (79.3%)
	Steroids	Methylprednisolon	e 5 (16.7%)	7 (24.1%)
		Prednisolon	e 2 (6.7%)	4 (13.8%)
		Othe		0 (0.0%)

*Patients may have received more than one concomitant medication

Table E1b: Adjuvant therapies day 1 to day	r 14.		
	Orbcel-C	Placebo	Total
	n=30	n=29	
Airway Pressure Release Ventilation	5 (16.7%)	6 (20.7%)	11 (18.6%)
High-frequency oscillatory ventilation	2 (6.7%)	0 (0.0%)	2 (3.4%)
Neuromuscular Blocking Drugs	23 (76.7%)	23 (79.3%)	46 (78.0%)
Inhaled Vasodilator	3 (10.0%)	6 (20.7%)	9 (15.3%)
Prone position	20 (66.7%)	16 (55.2%)	36 (61.0%)
ECMO/ECCO ₂ R	1 (3.3%)	2 (6.9%)	3 (5.1%)
No. (%) presented.			

Table E2: Timing of study drug administration	Treatmer	nt Group	
	Orbcel-C Placebo		
	n=30	n=29	
Duration between thaw and commencement of IMP administration (Minutes)	172.7 (55.6)	179.9 (45.4)	
Duration between thaw and completion of IMP administration (Minutes)	212.1 (54.4)	222.8 (45.4)	
Duration of infusion (Minutes)	39.4 (10.3) 37.5 (30 to 45)	42.9 (11.6) 40 (30 to 50)	
Duration between ICU admission and completion of IMP administration (Days)	3.2 (2.9)	2.5 (1.3)	
Duration between commencement of IMV and completion of IMP administration (Days)	1.9 (0.7)	2.0 (0.8)	
Mean (SD) or Median (IQR) reported			

	Number of	events	Number of	patients*	Risk Ratio (95%	p-value
	ORBCEL-C	Placebo	ORBCEL-C	Placebo	Confidence Interval	
		Adverse Ev	ents		•	•
Cardiac disorders	1	1	1 (3.3%)	1 (3.4%)	0.97 (0.06 to 14.7)	1.00
Gastrointestinal disorders	0	1	0 (0.0%)	1 (3.4%)	0 (-)	0.49
General disorders and administration site conditions	1	0	1 (3.3%)	0 (0.0%)	-	1.00
Respiratory, thoracic and mediastinal disorders	3	0	3 (10.0%)	0 (0.0%)	-	0.24
Vascular disorders	1	1	1 (3.3%)	1 (3.4%)	0.97 (0.06 to 14.7)	1.00
Blood and lymphatic system disorders	4	1	4 (13.3%)	1 (3.4%)	3.9 (0.5 to 32.6)	0.35
·		Serious Adverse	e Events		•	
Cardiac disorders	2	3	2 (6.7%)	3 (10.3%)	0.64 (0.1 to 3.6)	0.67
Gastrointestinal disorders	0	3	0 (0.0%)	3 (10.3%)	0 (-)	0.11
General disorders and administration site conditions	1	0	1 (3.3%)	0 (0.0%)	-	1.00
Hepatobiliary disorders	1	1	1 (3.3%)	1 (3.4%)	1.0 (0.06 to 14.7)	1.00
Infections and infestations	4	3	2 (6.7%)	3 (10.3%)	0.64 (0.1 to 3.6)	0.67
Injury, poisoning and procedural complications	0	1	0 (0.0%)	1 (3.4%)	0 (-)	0.49
Investigations	1	2	1 (3.3%)	2 (6.9%)	0.48 (0.05 to 5.0)	0.61
Nervous system disorders	3	0	3 (10.0%)	0 (0.0%)	-	0.24
Renal and urinary disorders	1	0	1 (3.3%)	0 (0.0%)	-	1.00
Respiratory, thoracic and mediastinal disorders	3	1	3 (10.0%)	1 (3.4%)	2.9 (0.3 to 26.3)	0.61
Skin and subcutaneous tissue disorders	1	0	1 (3.3%)	0 (0.0%)	-	1.00
Vascular disorders	2	1	2 (6.7%)	1 (3.4%)	1.9 (0.2 to 19.5)	1.00

Table E3b: F	ull listing of Adverse Ev	ents reported					
Allocation	AE term	System Organ Class	Severity	Causality	Expectedness	Serious	Study Day*
Orbcel-C	Internal Jugular Venous thrombosis	Blood and lymphatic system disorders	Mild (Grade 1)	Not related	N/A	No	19
	Drop in platelet	Blood and lymphatic	Mild				
Orbcel-C	level from 143 to 66	system disorders	(Grade 1)	Unlikely	N/A	No	12
		Blood and lymphatic	Moderate				
Orbcel-C	Anaemia	system disorders	(Grade 2)	Not related	N/A	No	4
Orbcel-C	Small clot in left subclavian vein	Blood and lymphatic system disorders	Mild (Grade 1)	Unlikely	N/A	No	38
			Moderate				
Orbcel-C	SVT and fast AF Non-sustained	Cardiac disorders	(Grade 2)	Not related	N/A	Yes	4
	Ventricular	a	Moderate				1.5
Orbcel-C	tachycardia	Cardiac disorders General disorders and	(Grade 2)	Not related	N/A	No	17
		administration site	Death				
Orbcel-C	Multi Organ Failure	conditions	(Grade 5)	Unlikely	N/A	Yes	13
010001-0		Hepatobiliary	Mild	Ollinkery	11///	103	15
Orbcel-C	Deranged LFTs	disorders	(Grade 1)	Not related	N/A	No	3
	Antibiotic resistant		(01000 1)				-
	Pseudomonas						
	aeruginosa on	Infections and	Moderate				
Orbcel-C	vascular line tip	infestations	(Grade 2)	Not related	N/A	No	10
	Vancomycin						
	resistant E. faecium	Infections and	Moderate				
Orbcel-C	in urine	infestations	(Grade 2)	Not related	N/A	No	13
	Antibiotic resistant						
	Klebsiella aerogenes						
	in bronchial lavage	Infections and	Moderate				
Orbcel-C	sample	infestations	(Grade 2)	Not related	N/A	No	7
		Infections and	Mild				
Orbcel-C	Pyrexia	infestations	(Grade 1)	Possibly	Expected	No	2
0.1.1.0	Deranged liver	Turrentin (Moderate	N-4 1 1 1			1
Orbcel-C	enzymes	Investigations	(Grade 2)	Not related	N/A	No	1
Orbest C	Right sided	Nervous system	Severe	Not rolated	NI/A	No	24
Orbcel-C	watershed infarcts	disorders Nervous system	(Grade 3) Mild	Not related	N/A	No	24
Orbcel-C	Myoclonic Jerks	disorders	(Grade 1)	Not related	N/A	No	3
010001-0	Wyociolite Jerks	Nervous system	Mild	Not related		110	5
Orbcel-C	Bilateral tremor	disorders	(Grade 1)	Not related	N/A	No	76
orbeer e	Acute on chronic	uisoruers		Rot Telated	10/21		/0
	kidney injury						
	requiring	Renal and urinary	Severe				
Orbcel-C	haemofiltration	disorders	(Grade 3)	Not related	N/A	No	1
		Respiratory, thoracic					
	Pneumomediastinu	and mediastinal	Death				
Orbcel-C	m	disorders	(Grade 5)	Not related	N/A	Yes	1
		Respiratory, thoracic					
	Haemorrhagic	and mediastinal	Moderate				
Orbcel-C	ARDS	disorders	(Grade 2)	Not related	N/A	Yes	12
		Respiratory, thoracic					
01.17	Respiratory	and mediastinal	Severe				
Orbcel-C	Deterioration	disorders	(Grade 3)	Unlikely	N/A	Yes	11
01.10	D I	Skin and subcutaneous	Mild				16
Orbcel-C	Rash	tissue disorders	(Grade 1)	Unlikely	N/A	No	16
01.10	Pulmonary	xx 1 1. 1	Severe				-
Orbcel-C	Embolism	Vascular disorders	(Grade 3)	Not related	N/A	No	5
	Pulmonary						
	embolism with non- occlusive thrombi in						
	the right lower lobe		Mild				
Orbcel-C	pulmonary artery.	Vascular disorders	(Grade 1)	Unlikely	N/A	Yes	15
01000-0	pannonary artory.	Blood and lymphatic	Moderate		11/11	105	15
Placebo	Haemoptysis	system disorders	(Grade 2)	Not related	N/A	No	5
. 100000		system disorders	Mild	litterated	11/11	1.0	
Placebo	Prolonged QTc	Cardiac disorders	(Grade 1)	Not related	N/A	No	27
		alboratio	Moderate			1	
Placebo	STEMI	Cardiac disorders	(Grade 2)	Not related	N/A	Yes	27
			Moderate				
	1	1			31/4		2
Placebo	AF	Cardiac disorders	(Grade 2)	Not related	N/A	INO	4
Placebo	AF	Cardiac disorders Gastrointestinal	(Grade 2) Moderate	Not related	N/A	No	2

	Small bowel hernia		1				
	with massively		Life-				
	distended loops of	Gastrointestinal	threatening				
Placebo	small bowel	disorders	(Grade 4)	Not related	N/A	Yes	10
		Gastrointestinal	Mild				
Placebo	PR Bleed - Enteritis	disorders	(Grade 1)	Not related	N/A	No	9
		Hepatobiliary	Moderate				-
Placebo	Acute Liver Failure	disorders	(Grade 2)	Not related	N/A	No	17
	Ventilator Aquired						
	Pneumonia		Life-				
	diagnosis -	Infections and	threatening				
Placebo	Klebsiella in sputum	infestations	(Grade 4)	Unlikely	N/A	No	9
		Infections and	Moderate				
Placebo	CMV viraemia	infestations	(Grade 2)	Not related	N/A	No	16
		Infections and	Mild				
Placebo	Pyrexic	infestations	(Grade 1)	Possibly	Expected	No	2
	Ulcerated lesion on	Injury, poisoning and					
	the posterior	procedural	Mild				
Placebo	tracheal wall	complications	(Grade 1)	Not related	N/A	No	28
	Fibrotic lung disease						
	secondary to covid		Moderate				
Placebo	19	Investigations	(Grade 2)	Not related	N/A	No	27
	Baseline						
	temperature						
	unrecordable-						
	patient being						
	actively warmed						
	with bair hugger-						
	15mins into IMP		Mild				
Placebo	infusion patient temperature 33.9	Investigations	(Grade 1)	Unlikely	N/A	No	1
Placebo	Bilateral	Investigations	(Grade I)	Uninkery	IN/A	INO	1
	pneumothoraces and						
	pneumomediastinum	Respiratory, thoracic					
	secondary to	and mediastinal	Moderate				
Placebo	barotrauma	disorders	(Grade 2)	Not related	N/A	No	16
1 100000	Right Lower Lobe	415014015	Moderate	1.01 Iolatou	11/21	110	10
Placebo	Pulmonary Emboli	Vascular disorders	(Grade 2)	Not related	N/A	Yes	28
1 100000	1 amonary Emoon			1 tot totatou	11/11	105	20

Table E4a: Venous Thromboembolism (VTE) and Pulmonary Emboli reported as safety event						
	No. of Events No. of Patients					
	ORBCEL-C	Placebo	ORBCEL-C	Placebo		
Deep Vein Thrombosis*	2	0	2	0		
Pulmonary Embolism 2 1 2 1						
*includes internal ingular	venous thrombosis and left	subclavian vein thrombus				

Table E4b: Detailed asse	essment of Venous Thr	omboembolism (VTE) and Puln	nonary Emboli rep	orted as safety ev	ent	-
Event Description	Treatment group	System Organ Class	Time of event	Causality	Expectedness	Classification
Right lower lobe pulmonary emboli	Placebo	Vascular disorders	Day 28	Not related	Unexpected	Moderate (Grade 2)
Pulmonary emboli	ORBCEL-C	Vascular disorders	Day 5	Not related	Unexpected	Severe (Grade 3)
Pulmonary embolism with non-occlusive thrombi in right lower lobe pulmonary artery	ORBCEL-C	Vascular disorders	Day 15	Unlikely	Unexpected	Mild (Grade 1)
Left subclavian vein thrombus	ORBCEL-C	Blood and lymphatic system disorders	Day 38	Unlikely	Unexpected	Mild (Grade 1)
Internal jugular vein thrombus	ORBCEL-C	Blood and lymphatic system disorders	Day 19	Not related	Unexpected	Mild (Grade 1)

Table E5a: Adjusted analysis for Oxygenation I	ndex (cmH2O/kPa) at day 7			
	ORBCEL-C n=30	Placebo n=29	Mean Difference (95% CI)	p-value
Imputed				
Last value carried forward	96.0 (11.6)	98.9 (11.8)	-2.9 (-36.6 to 30.8)	0.86
Minimum value	88.7 (12.3)	90.0 (12.5)	-1.3 (-36.9 to 34.3)	0.94
Maximum value	109.9 (13.5)	133.0 (13.8)	-23.1 (-62.2 to 16.1)	0.24
Mean substitution	97.6 (11.4)	106.0 (11.2)	-8.5 (-40.9 to 24.0)	0.60
			-33.1	
Observed values	108.6 (17.0)	141.7 (20.3)	(-89.8 to 23.6)	0.24
Mean (SE) presented for the adjusted analysis (a	adjusted for baseline age, PF	Ratio, APACHE II and v	vasopressor use) in the inten	tion-to-treat population.

Table E5b: Post-hoc adjusted an	alysis for Oxygenation In	ndex (cmH ₂ O/kPa) at da	y 7 (to include site)	
	ORBCEL-C n=30	Placebo n=29	Mean Difference	p-value
			(95% CI)	
Last value carried forward	98.3 (10.4)	96.6 (12.5)	1.2 (-32.6 to 35.0)	0.94
Observed values	108.1 (20.2)	142.3 (24.6)	-34.2 (-107.8 to 39.5)	0.34
Mean (SE) presented for the adj	usted analysis (adjusted f	or baseline age, PF Rat	io, APACHE II, vasopressor	use, and
site) in the intention-to-treat pop	ulation.			

Table E5c: Reasons for missing observed data for Oxygenation Index at day 7					
	ORBCEL-C	Placebo			
Death	1	1			
Extubation	2	2			
Pressure support ventilation	8	12			
ICU discharge	0	1			
Missing data	1	0			

Table E5d: Seconda	Table E5d: Secondary analysis of oxygenation index (cmH ₂ O/kPa) at day 7 in a per protocol population									
	Unadjusted, Mean (SD)		Unadjusted, Mean (SD) Mean		Mean		Adjusted, Mean	u (SE)‡	Mean	
	ORBCEL-C n=29*	Placebo n=29	Difference (95% CI)	p-value	ORBCEL-C	Placebo	Difference (95% CI)	p-value		
Observed values	118.5 (66.4) n=17	129.4 (87.8) n=13	-10.9 (-68.5 to 46.7)	0.70	108.7 (18.0)	142.3 (20.8)	-33.6 (-92.9 to 25.6)	0.25		
Imputed values	98.3 (58.2)	96.6 (67.3)	1.7 (-31.4 to 34.8)	0.92	95.9 (12.0)	98.9 (11.9)	-3.0 (-37.3 to 31.4)	0.86		

Per protocol analyses which includes only those patients who completed the study drug infusion. *n=1 in ORBCEL-C group had study drug administration terminated early by the treating physician as sediment was noted in the infusion filter, therefore n=29 were included in the per-protocol analysis. *Adjusted for baseline age, PF Ratio, APACHE II and Vasopressor Use

Table E5e: Addition	al analysis of oxy	genation index (cmH ₂ O/kPa) at day	7 in patients	with confirmed P	CR COVID-19		
	Unadjusted, Me	Unadjusted, Mean (SD)		Mean Difference p-value Adj (95% CI)		Adjusted, Mean (SE)*		p-value
	ORBCEL-C n=30	Placebo n=27			ORBCEL-C	Placebo		
Observed values	117.4 (64.5) n=18	129.4 (87.8) n=13	-12.0 (-67.8 to 43.9)	0.66	108.6 (17.0)	141.7 (20.3)	-33.1 (-89.8 to 23.6)	0.24
Imputed Values				•			· · ·	
Last value carried forward	98.3 (57.2)	99.6 (68.5)	-1.3 (-34.7 to 32.1)	0.94	96.4 (11.7)	101.7 (12.4)	-5.3 (-39.8 to 29.2)	0.76
Minimum value	91.0 (60.3)	91.0 (72.4)	0.04 (-35.2 to 35.3)	1.00	89.3 (12.4)	92.9 (13.1)	-3.6 (-40.1 to 32.9)	0.84
Maximum value	111.8 (55.3)	134.7 (88.4)	-23.0 (-61.7 to 15.8)	0.24	108.9 (13.0)	138.0 (13.7)	-29.2 (-67.5 to 9.2)	0.13
Mean substitution	100.0 (55.3)	106.6 (65.6)	-6.6 (-38.7 to 25.5)	0.68	97.7 (11.2)	109.1 (11.8)	-11.4 (-44.3 to 21.5)	0.49
*Adjusted for age, P	F Ratio, APACHI	E II and Vasopre	essor Use					

	Treatmen			
	ORBCEL-C n=30	Placebo n=29	- Mean Difference (95% Confidence Interval)	p-value
Oxygenation Ind	ex (cmH ₂ O/kPa)	I	1	
Day 4	90.9 (23.5) n=17	91.4 (33.8) n=21	0.5 (-19.1 to 20.2)	0.96
Day 14	92.3 (43.9) n=11	170.8 (170.8) n=4	78.5 (-35.9 to 192.9)	0.16
Respiratory com	pliance (ml/cmH ₂ O)			
Day 4	30.9 (8.2) n=16	33.5 (19.5) n=19	2.6 (-8.0 to 13.2)	0.62
Day 7	47.4 (45.0) n=18	27.8 (8.7) n=11	-19.6 (-47.9 to 8.7) -6.6	0.17
Day 14	26.8 (12.7) n=11	20.2 (4.4) n=3	-6.6 (-23.3 to 10.0)	0.40
Driving Pressure	(cmH ₂ O)			
Day 4	14.7 (3.9) n=16	13.9 (5.2) n=19	-0.8 (-4.0 to 2.4)	0.62
Day 7	13.1 (6.5) n=18	14.5 (3.4) n=11	1.5 (-2.9 to 5.8) 2.4	0.49
Day 14	18.0 (6.3) n=11	20.3 (1.5) n=3	2.4 (-5.9 to 10.6)	0.54
PF ratio (PaO ₂ /Fi	.O ₂)			
Day 4	19.6 (4.5) n=29	21.4 (7.2) n=28	1.9 (-1.3 to 5.0) 1.2	0.25
Day 7	18.2 (5.9) n=28	19.3 (6.2) n=27	1.2 (-2.1 to 4.5)	0.47
Day 14	26.6 (12.3) n=23	22.6 (6.3) n=17	-4.0 (-10.6 to 2.6)	0.23
Sequential Organ	Failure Assessment (SOF			
Day 4	6.0 (3.5) n=26	6.5 (3.5) n=27	0.6 (-1.4 to 2.5)	0.56
Day 7	5.9 (3.7) n=28	5.8 (3.2) n=21	-0.05 (-2.1 to 2.0) -0.7	0.96
Day 14	6.2 (3.8) n=21	5.5 (2.4) n=15	-0.7 (-2.9 to 1.6)	0.56

		ORBCEL-C n=30	Placebo n=29	Mean Difference (99% Confidence Intervals)	Interaction Term
CRP (mg/L)	< median	77.7 (28.5) n=14	74.4 (23.5) n=15	3.3 (-56.0 to 62.6)	0.90
	\geq median	116.4 (69.8) n=16	116.8 (92.1) n=13	-0.4 (-60.0 to 59.2)	_
Ferritin (ng/ml)	<1500	77.8 (24.0) n=9	87.8 (29.3) n=6	-10.0 (-53.0 to 33.1)	0.070
	≥1500	108.4 (16.0) n=4	77.5 (38.3) n=7	30.9 (-20.3 to 82.1)	
PF ratio (PaO ₂ /FiO ₂)	<20	108.3 (62.4) n=22	83.6 (29.1) n=15	24.6 (-30.4 to 79.6)	0.056
< <i></i>	≥20	71.1 (26.1) n=8	110.4 (91.9) n=14	-39.3 (-112.1 to 33.5)	

			Treatment Group		Mean Difference/Risk Ratio	Interaction Term
			ORBCEL-C	Placebo	(99% Confidence Intervals)	
entilation Free	CRP (mg/L)	< median	4.0	7.0		0.28
ays at day 28*			(0.0-15.0)	(0.0-18.0)	-0.7 (-8.8 to 7.3)	
			8.0 (9.2)	8.7 (9.1)		
			n=14	n=15		
		\geq median	3.5	10.0		
			(0.0-9.5)	(0.0-18.0)	-5.2 (-13.3 to 2.9)	
			4.5 (4.7)	9.7 (8.9)		
			n=16	n=13		
	Ferritin (ng/ml)	<1500	0.0	11.5		0.25
			(0.0-12.0)	(0.0-13.0)		
			52(78)	0.0 (0.0)	-4.5 (-16.0 to 7.0)	
			5.3 (7.8) n=9	9.8 (8.8) n=6		
		≥1500	95	0.0		1
			(4.5-10.0)	(0.0-10.0)		
					2.3 (-11.4 to 15.9)	
			7.3 (4.9)	5.0 (8.0)		
		ļ	n=4	n=7		
	PF ratio	<20	0.0	10.0		0.034
	(PaO ₂ /FiO ₂)		(0.0-9.0)	(0.0-18.0)	57(127(14)	
			4.3 (6.7)	10.0 (8.7)	-5.7 (-12.7 to 1.4)	
			n=22	n=15		
		≥20	12.0	4.0		1
			(6.5-15.5)	(0.0-18.0)		
					3.5 (-5.8 to 12.8)	
			11.1 (6.9)	7.6 (9.2)		
			n=8	n=14		
3 day	CRP (mg/L)	< median	2 (14.3%)	5 (33.3%)	0.4 (0.06 to 3.0)	0.16
ortality**		> madieu	n=14	n=15	$24(0.1 \pm 240.7)$	4
		\geq median	3 (18.8%) n=16	1 (7.7%) n=13	2.4 (0.1 to 40.7)	
	Ferritin (ng/ml)	<1500	1 (11.1%)	1 (16.7%)	0.7 (0.02 to 19.6)	-
		1500	n=9	n=6	0.7 (0.02 to 19.0)	
		≥1500	0 (0.0%)	2 (28.6%)	-	1
			n=4	n=7		
	PF ratio	<20	5 (22.7%)	3 (20.0%)	1.1 (0.2 to 6.0)	-
	(PaO ₂ /FiO ₂)		n=22	n=15		
		≥20	0 (0.0%)	3 (21.4%)	-	
	 an (IQR) or n (%) pr		n=8	n=14		

Table E0. Description of Simificant Medical Encode
Table E9: Description of Significant Medical Events

	ORBCEL-C	Placebo
Number followed up at 1 year	20	21
Number followed up at 2 years	20	20
Total No. of events	14	11
Total No. of patients (n,%)	11/20 (55)	9/21 (43)
Cardiac Disorders	1	0
Infection	2	1
Fracture	2	1
Gastrointestinal disorder	0	1
Neoplasm	3	0
Hyperglycaemia	1	1
Renal and urinary disorder	1	1
Respiratory Disorders (Pulmonary Fibrosis)	4	6
&For n=1 in the placebo follow up for SMEs was only	v to year 1 as the patient withdrew consent for	or SME follow up at year 2

*For n=1 in the placebo follow up for SMEs was only to year 1 as the patient withdrew consent for SME follow up at year 2

Table E10: Clinical Laboratory Asse	ssments at day 0, 4, 7, and 14	
	ORBCEL-C	Placebo
	n=30	n=29
AST (U/L)		
Day 0	37.3 (22.7)	43.5 (41.2)
	n=16 61.1 (48.8)	n=15 48.7 (36.8)
Day 4	n=15	n=13
Day 7	46.1 (28.1)	42.1 (18.4)
	<u>n=16</u> 45.1 (27.1)	n=14 64.6 (80.1)
Day 14	43.1(27.1) n=14	n=8
ALT (U/L)		
Day 0	42.2 (22.5)	40.9 (31.3)
	n=20	n=18
Day 4	54.3 (22.4) n=13	59.3 (49.7) n=11
Day 7	59.1 (29.3)	56.4 (36.1)
Day 7	n=15	n=8
Day 14	58.5 (43.4) n=11	113.6 (83.4) n=8
ALP (U/L)		1 0
Day 0	91.2 (54.8)	86.5 (41.6)
	n=28	n=27
Day 4	102.7 (49.2) n=23	88.3 (36.9) n=24
	105.9 (50.7)	85.9 (39.2)
Day 7	n=26	n=21
Day 14	125.3 (83.6) n=20	115.9 (64.3)
CRP (mg/L)	II-20	n=17
Day 0	145.3 (109.6)	136.6 (103.0)
	× /	n=28
Day 4	85.2 (99.2) n=23	86.8 (105.6)
	136.8 (130.0)	n=23 94.0 (109.9)
Day 7	n=24	n=20
Day 14	101.9 (80.5)	90.5 (71.2)
PT (s)	n=21	n=16
Day 0	11.7 (1.4)	12.5 (2.1)
24,7 0	n=22	n=20
Day 4	11.7 (1.4)	11.7 (1.5)
-	n=19 11.5 (1.0)	n=14 11.8 (1.7)
Day 7	n=17	n=14
Day 14	11.7 (1.0)	10.7 (3.6)
APTT (s)	n=13	n=10
Day 0	26.2 (5.6)	29.5 (6.6)
24,0	n=25	n=23
Day 4	28.8 (14.4)	24.7 (8.1)
	n=19 23.9 (8.9)	n=18 26.4 (6.5)
Day 7	n=19	n=17
Day 14	29.8 (19.6)	25.3 (9.7)
Fibrinogen (g/l)	n=17	n=12
Day 0	5.7 (1.7)	5.4 (1.6)
Day 0	n=24	n=21
Day 4	5.3 (1.3)	4.7 (1.5)

	n=19	n=12
Day 7	6.6 (1.9)	5.6 (1.9)
Day /	n=15	n=15
Day 14	6.3 (1.2)	5.8 (1.8)
Hb (g/L)	n=13	n=12
	11(0(157)	11(1(157)
Day 0	116.0 (15.7)	116.1 (15.7)
Day 4	108.8 (18.7)	109.4 (16.7)
Day 4	n=28	n=25
Day 7	107.3 (19.7) n=29	106.7 (18.2) n=25
D 14	94.2 (17.0)	94.6 (15.2)
Day 14	n=23	n=18
WBC (x10 ⁹ /L)		
Day 0	12.3 (7.3)	11.7 (5.2)
	11.7 (4.2)	12.4 (5.8)
Day 4	n=28	n=25
Day 7	15.2 (6.3)	13.0 (5.3)
	n=29	n=25
Day 14	12.1 (4.5) n=23	11.2 (3.7) n=18
Neutrophils (x10 ⁹ /L)	11 20	
Day 0	10.9 (7.5)	10.2 (4.9)
Day 4	9.2 (2.9)	10.6 (5.5)
	n=27 13.1 (6.0)	n=25 10.7 (5.0)
Day 7	n=29	n=25
D 14	9.1 (4.1)	8.8 (3.4)
Day 14	n=22	n=18
Highest Urea (mmol/L)		
Day 0	12.9 (6.9)	11.6 (5.3)
	13.2 (5.7)	15.2 (6.4)
Day 4	n=27	n=25
Day 7	12.1 (3.9)	15.8 (11.0)
2.0,7	n=28 16.1 (11.3)	n=25
Day 14	n=24	15.0 (6.8) n=18
Lowest eGFR (mL/min)	11 24	
Day 0	58.8 (27.7)	67.7 (21.0)
, , , , , , , , , , , , , , , , , , ,	n=28	n=28
Day 4	62.8 (27.4)	68.8 (23.7)
	n=25 68.0 (27.4)	n=26 67.9 (25.3)
Day 7	n=28	n=23
Day 14	63.5 (34.9)	72.2 (24.4)
	n=24	n=18
Ferritin (ng/ml)		
Day 0	1394.5 (617.4) n=13	1728.8 (997.0) n=13
	844.7 (357.3)	1617.1(1813.1)
Day 4	n=6	n=8
Day 7	1020.0 (434.2)	808.4 (901.2)
Duy /	n=11	n=13
Day 14	569.2 (254.1) n=6	1284.6 (1687.4) n=10
Mean (SD) presented.	11-0	1 11-10

Supplemental Figure Legends

Figure E1: Screening and recruitment data for each clinical site.

Figure E2: Post infusion parameters

Mean (SD) for Temperature (A), FiO₂ (B), PEEP (C), Oxygen Saturation (D), Plateau

Pressure (E), PaO₂ (F), PaCO₂ (G), Heart Rate (H), Systolic Blood Pressure (I) and Diastolic

Blood Pressure (J) following administration of the study drug are presented. Repeated

measures ANOVA demonstrated plateau pressure differed significantly over time (p=0.01).

No other differences over time or between treatment groups were significant (p < 0.05).

Figure E3: Pulmonary and non-pulmonary organ function

PaO₂/FiO₂ (PF) ratio (A), Respiratory compliance (B), Driving pressure (C), and SOFA score (D)

at day 0, 4, 7, and 14. Mean (SD) are presented.

Figure E4: Clinical laboratory measurements.

White Blood Cells, WBC (A), and C-Reactive Protein, CRP (B), over time up to day 14. Mean

(SD) are presented. Between group comparison by repeated measures ANOVA demonstrated no

difference between the ORBCEL-C and placebo group over time from day 0 to day 14 (CRP

p=0.70, WBC p=0.85).

Figure E5: Clinical laboratory measurements of coagulation.

Prothrombmin Time, PT (A), Activated Partial Thromboplastin Time, APTT (B), and Fibrinogen

(C) over time up to day 14. Mean (SD) are presented.

Figure E6: Heatmap highlighting the magnitude of expression of DEGs and the overlap between the treatment groups.

Figure E7: Transcriptomic analysis - Deconvolution of immune cell populations

Boxplots depicting the expression of immune cell populations at baseline (D0), day 4 (D4) and day 7 (D7) in ORBCEL-C (pink) and placebo (lemon) groups, generated using the deconvolution package *Immunostates*.




Figure E2




Figure E2 (continued)




Figure E3





Figure E4






Figure E5





Figure E6



ORBCEL-C	Placebo

Figure E7

